View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Feb. 22, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	LNTH
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Central Index Key	0001521036
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		37,860,711
Entity Public Float			$ 541.6

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 76,290	$ 51,178
Accounts receivable, net	40,259	36,818
Inventory	26,080	17,640
Other current assets	5,221	5,183
Total current assets	147,850	110,819
Property, plant & equipment, net	92,999	94,187
Intangibles, net	11,798	15,118
Goodwill	15,714	15,714
Deferred tax assets, net	87,010	65
Other long-term assets	28,487	19,995
Total assets	383,858	255,898
Current liabilities
Current portion of long-term debt	2,750	3,650
Revolving line of credit	0	0
Accounts payable	17,464	18,940
Accrued expenses and other liabilities	26,536	21,249
Total current liabilities	46,750	43,839
Asset retirement obligations	10,412	9,370
Long-term debt, net	265,393	274,460
Other long-term liabilities	38,012	34,745
Total liabilities	360,567	362,414
Commitments and contingencies (see Note 14)
Stockholders’ equity (deficit)
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 37,765 and 36,756 shares issued and outstanding, respectively)	378	367
Additional paid-in capital	232,960	226,462
Accumulated deficit	(209,013)	(332,398)
Accumulated other comprehensive loss	(1,034)	(947)
Total stockholders’ equity (deficit)	23,291	(106,516)
Total liabilities and stockholders’ equity (deficit)	$ 383,858	$ 255,898

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	37,765,000	36,756,000
Common stock, shares outstanding (in shares)	37,765,000	36,756,000

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues	$ 331,378	$ 301,853	$ 293,461
Cost of goods sold	169,243	164,073	157,939
Gross profit	162,135	137,780	135,522
Operating expenses
Sales and marketing	42,315	36,542	34,740
General and administrative	49,842	38,832	43,894
Research and development	18,125	12,203	14,358
Total operating expenses	110,282	87,577	92,992
Gain on sales of assets	0	6,385	0
Operating income	51,853	56,588	42,530
Interest expense	18,410	26,618	38,715
Debt retirement costs	0	1,896	0
Loss on extinguishment of debt	2,442	0	15,528
Other (income) expense	(8,638)	(220)	65
Income (loss) before income taxes	39,639	28,294	(11,778)
Income tax (benefit) provision	(83,746)	1,532	2,968
Net income (loss)	$ 123,385	$ 26,762	$ (14,746)
Net income (loss) per common share:
Basic (in dollars per share)	$ 3.31	$ 0.84	$ (0.60)
Diluted (in dollars per share)	$ 3.17	$ 0.82	$ (0.60)
Weighted-average common shares outstanding:
Basic (in shares)	37,276	32,044	24,440
Diluted (in shares)	38,892	32,656	24,440

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 123,385	$ 26,762	$ (14,746)
Other comprehensive (loss) income:
Reclassification adjustment for gains on sales of assets included in net income	0	435	0
Foreign currency translation	(87)	603	(355)
Total other comprehensive (loss) income	(87)	1,038	(355)
Comprehensive income (loss)	$ 123,298	$ 27,800	$ (15,101)

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	IPO	Common Stock	Common Stock IPO	Treasury Stock	Additional Paid-In Capital	Additional Paid-In Capital IPO	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2014			18,081,000		(5,000)
Beginning balance at Dec. 31, 2014	$ (239,270)		$ 181		$ (106)	$ 106,699		$ (344,414)	$ (1,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			40,000	12,257,000
Issuance of common stock	0	$ 67,177	$ 0	$ 122			$ 67,055
Treasury stock retired (in shares)					5,000
Treasury stock retired	0				$ 106	(106)
Net income (loss)	(14,746)							(14,746)
Other comprehensive income (loss)	$ (355)								(355)
Stock option exercises (in shares)	0
Shares withheld to cover taxes (in shares)			(13,000)
Shares withheld to cover taxes	$ (97)		$ 0			(97)
Stock-based compensation	2,002					2,002
Ending balance (in shares) at Dec. 31, 2015			30,365,000		0
Ending balance at Dec. 31, 2015	(185,289)		$ 303		$ 0	175,553		(359,160)	(1,985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			6,200,000
Issuance of common stock	48,820		$ 62			48,758
Net income (loss)	26,762							26,762
Other comprehensive income (loss)	$ 1,038								1,038
Stock option exercises (in shares)	40,976
Stock option exercises	$ 231		$ 1			230
Vesting of restricted stock awards (in shares)			214,000
Vesting of restricted stock awards	0		$ 2			(2)
Shares withheld to cover taxes (in shares)			(64,000)
Shares withheld to cover taxes	(602)		$ (1)			(601)
Stock-based compensation	2,524					2,524
Ending balance (in shares) at Dec. 31, 2016			36,756,000		0
Ending balance at Dec. 31, 2016	(106,516)		$ 367		$ 0	226,462		(332,398)	(947)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	123,385							123,385
Other comprehensive income (loss)	$ (87)								(87)
Stock option exercises and employee stock plan purchases (in shares)	478,000
Stock option exercises and employee stock plan purchases	$ 3,434		$ 5			3,429
Stock option exercises (in shares)	465,232
Vesting of restricted stock awards (in shares)			744,000
Vesting of restricted stock awards	$ 0		$ 8			(8)
Shares withheld to cover taxes (in shares)			(214,000)
Shares withheld to cover taxes	(2,853)		$ (2)			(2,851)
Stock-based compensation	5,928					5,928
Ending balance (in shares) at Dec. 31, 2017			37,765,000		0
Ending balance at Dec. 31, 2017	$ 23,291		$ 378		$ 0	$ 232,960		$ (209,013)	$ (1,034)

Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Issuance costs	$ 2,080
IPO
Issuance costs		$ 6,362

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities
Net income (loss)	$ 123,385	$ 26,762	$ (14,746)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
Depreciation, amortization and accretion	19,231	18,263	19,651
Amortization of debt related costs	1,361	1,603	2,431
Write-off of deferred offering and financing costs	0	0	236
Provision for bad debt	136	53	773
Provision for excess and obsolete inventory	1,215	1,342	1,359
Stock-based compensation	5,928	2,524	2,002
Gain on sales of assets	0	(6,385)	0
Loss on impairment of land	912	0	0
Loss on extinguishment of debt and debt retirement costs	2,442	1,896	15,528
Deferred taxes	(86,946)	(155)	99
Long-term income tax receivable	(8,413)	(200)	230
Long-term income tax payable and other long-term liabilities	2,793	565	638
Other	1,049	1,284	1,795
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	(3,407)	(1,059)	(14)
Inventory	(9,620)	(3,626)	(2,609)
Other current assets	(388)	(155)	(132)
Accounts payable	604	5,700	(1,680)
Income taxes	(30)	(112)	187
Accrued expenses and other liabilities	4,525	1,342	(3,986)
Net cash provided by operating activities	54,777	49,642	21,762
Investing activities
Capital expenditures	(17,543)	(7,398)	(13,151)
Proceeds from sale of assets	1,234	10,605	0
Other	0	74	0
Net cash (used in) provided by investing activities	(16,309)	3,281	(13,151)
Financing activities
Proceeds from issuance of common stock	187	50,900	73,539
Payments for public offering costs	(74)	(2,006)	(6,925)
Proceeds from issuance of long-term debt	274,313	0	360,438
Payments on long-term debt	(286,694)	(78,729)	(1,900)
Payments on senior notes	0	0	(400,000)
Payment for call premium on senior notes	0	0	(9,752)
Deferred financing costs	(1,576)	(11)	(6,304)
Net movement in line of credit	0	0	(8,000)
Proceeds from stock option exercises	3,247	231	0
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(2,853)	(602)	(97)
Net cash (used in) provided by financing activities	(13,450)	(30,217)	999
Effect of foreign exchange rates on cash and cash equivalents	94	(124)	(753)
Net increase in cash and cash equivalents	25,112	22,582	8,857
Cash and cash equivalents, beginning of year	51,178	28,596	19,739
Cash and cash equivalents, end of year	76,290	51,178	28,596
Supplemental disclosure of cash flow information
Interest	16,653	24,441	40,788
Income taxes, net of refunds of $17, $82 and $363, respectively	106	265	174
Schedule of non-cash investing and financing activities
Additions of property, plant & equipment included in liabilities	2,738	4,990	1,125
Receivable in connection with sale of Australian subsidiary	$ 0	$ 1,479	$ 0

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Cash Flows [Abstract]
Income taxes, refunds	$ 17	$ 82	$ 363

Description of Business

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), also a Delaware corporation.

The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and other products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The Company sells its products globally and has operations in the U.S., Puerto Rico and Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific and Latin America.

The Company has a portfolio of nine commercial products, which are diversified across a range of imaging modalities. The Company’s imaging agents include an ultrasound contrast agent and medical radiopharmaceuticals (including Technetium generators), including the following:

•

DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the U.S., is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.


•	TechneLite is a self-contained system, or generator, of Technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.


•	Xenon Xe 133 Gas (“Xenon”) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.


•	Neurolite is an injectable, Technetium-labeled imaging agent used with Single Photon Emission Computed Tomography (“SPECT”) technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.


•	Cardiolite is an injectable, Technetium-labeled imaging agent, also known by its generic name sestamibi, used with SPECT technology in myocardial perfusion imaging (“MPI”) procedures that assess blood flow distribution to the heart.

In the U.S., the Company sells DEFINITY through its direct sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through third-party commercial radiopharmacies.

The Company’s International operations consist of sales directly to end users through its wholly-owned radiopharmacy in Puerto Rico and sales through the Company’s distributors in Europe, Canada, Australia, Asia-Pacific and Latin America.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Reclassifications

Certain immaterial reclassifications have been made to conform the prior year consolidated financial statements and notes to the current year presentation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which all revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time all criteria have been met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.

Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.

Collaboration and License Agreement with GE Healthcare Limited

On April 25, 2017, the Company announced that it entered into a definitive, exclusive Collaboration and License Agreement (the “License Agreement”) with GE Healthcare Limited (“GE Healthcare”) for the continued Phase 3 development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography myocardial perfusion imaging agent that may improve the diagnosis of coronary artery disease. Under the License Agreement, GE Healthcare will complete the worldwide development of flurpiridaz F 18, pursue worldwide regulatory approvals and, if successful, lead a worldwide launch and commercialization of the agent, with LMI collaborating on both development and commercialization through a joint steering committee. LMI has an option to co-promote the agent in the U.S. GE Healthcare’s development plan will initially focus on obtaining regulatory approval for flurpiridaz F 18 in the U.S., Japan, Europe and Canada.

Under the terms of the License Agreement, the Company received an up-front payment of $5.0 million. In addition, the Company is eligible to receive, from GE Healthcare, up to $60 million in regulatory and sales-based milestones and tiered double-digit royalties on U.S. sales and mid-single digit royalties on sales outside the U.S. The Company has concluded that there was only one significant deliverable under the License Agreement, the license of the product, which was considered delivered upon the signing of the License Agreement. The Company recognized revenue of $5.0 million associated with entering into the license during the year ended December 31, 2017. In addition, because the Company concluded that the regulatory and sales-based milestones are solely dependent on GE Healthcare’s performance and that there are no continuing performance obligations from the Company, all development and sales milestones under the License Agreement are considered non-substantive. As of December 31, 2017, the Company has not recognized revenue for those milestones under the License Agreement and will recognize such revenue in the periods in which the milestones are achieved. Similarly, the Company will recognize royalty revenues in the periods of the sale of the related products, provided that the reported sales are reliably measurable, collectability is reasonably assured and the Company has no further performance obligations.

Product Returns

The Company provides a reserve for its estimate of sales recorded for which the related products are expected to be returned. The Company does not typically accept product returns unless an over‑shipment, non‑conforming shipment or shipment of defective goods has been provided to the customer. The Company adjusts its estimate of product returns if it becomes aware of other factors that could significantly impact its expected returns, including product recalls. These factors include its estimate of actual and historical return rates for non-conforming product and open return requests. Historically, the Company’s estimates of returns have approximated actual returns.

Shipping and Handling Revenues and Costs

The Company typically does not charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in revenues. Shipping and handling costs are included in cost of goods sold and were $14.3 million, $13.6 million and $17.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Accounts Receivable

Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues.

Also included in accounts receivable are miscellaneous receivables of $0.8 million and $0.7 million as of December 31, 2017 and 2016, respectively.

Rebates and Allowances

Estimates for rebates and allowances represent the Company’s estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenues and the establishment of a liability which is included in accrued expenses and other liabilities in the accompanying consolidated balance sheets. These rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for certain products, administration fees of group purchasing organizations and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s buying patterns and the resulting applicable contractual rebate or commission rate(s) to be earned over a contractual period.

Income Taxes

The Company accounts for income taxes using an asset and liability approach. The income tax (benefit) provision represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.

Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves the weighing of both positive and negative evidence concerning both historical and prospective information with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.

The Company accounts for uncertain tax positions using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company classifies interest and penalties within the income tax (benefit) provision.

Net Income (Loss) per Common Share

Basic earnings per common share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

Cash and Cash Equivalents

Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.

Concentration of Risks and Limited Suppliers

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to large national distributors, which in turn, may resell the Company’s products.

The following table sets forth customers representing 10% or more of accounts receivable and 10% or more of revenues:



	Accounts Receivable December 31,		Revenues Year Ended December 31,
	2017	2016	2017	2016	2015
Company A	***	***	12.0%	10.3%	11.3%
Company B	14.5%	13.1%	10.4%	11.4%	11.9%
Company C	***	10.5%	10.3%	***	***

________________________________

*** Amount represented less than 10% for the reporting period.

The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.

Historically, an important supplier of Moly and Xenon was Nordion, which relied on the NRU reactor in Chalk River, Ontario. As a result of a decision by the Government of Canada, the NRU reactor exited the medical isotope business in November 2016. The Company currently has Moly supply agreements with NTP Radioisotopes (“NTP”) of South Africa, for itself and on behalf of its subcontractor ANSTO of Australia, running through December 31, 2020, and with Institute for Radioelements (“IRE”) of Belgium, running through December 31, 2018 and renewable by us on a year-to-year basis thereafter. The Company also has a Xenon supply agreement with IRE which runs through June 30, 2019, also subject to extensions. The Company currently relies on IRE as the sole supplier of bulk-unprocessed Xenon which the Company processes and finishes for its customers. The Company currently relies on JHS as its sole source manufacturer of DEFINITY, Neurolite, Cardiolite and evacuation vials for TechneLite. The Company currently has no other active supplier of DEFINITY, Neurolite or Cardiolite.

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:



	Year Ended December 31,
	2017	2016	2015
DEFINITY	47.5%	43.6%	38.1%
TechneLite	31.6%	32.9%	24.7%
Xenon	***	***	16.7%

________________________________

*** Amount represented less than 10% of revenues for the reporting period

Inventory

Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost or market on a first-in, first-out basis.

The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. At December 31, 2017 and 2016, the Company had no capitalized inventories associated with product that did not have regulatory approval.

Property, Plant & Equipment

Property, plant & equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization is computed on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are as follows:



Class		Range of Estimated Useful Lives
Buildings		10 - 50 years
Land improvements		15 - 40 years
Machinery and equipment		3 - 15 years
Furniture and fixtures		15 years
Leasehold improvements		Lesser of lease term or 15 years
Computer software		3 - 5 years

Upon retirement or other disposal of property, plant & equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.

Included within machinery, equipment and fixtures are spare parts. Spare parts include replacement parts relating to plant & equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset.

Goodwill

Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that they may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. All goodwill has been allocated to the U.S. reporting unit.

In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. To conduct the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company did not recognize any goodwill impairment charges during the years ended December 31, 2017, 2016 or 2015.

Intangible and Long-Lived Assets

The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.

Intangible assets, consisting of patents, trademarks and customer relationships related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.

Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.

Fair Values of Financial Instruments

The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company’s long term debt approximates its carrying values as the applicable interest rates are subject to change with market interest rates.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2017, 2016 and 2015, the Company incurred $4.4 million, $3.6 million and $3.1 million, respectively in advertising and promotion costs, which are included in sales and marketing in the consolidated statements of operations.

Research and Development

Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.

Foreign Currency

The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.

Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other (income) expense, in the consolidated statements of operations.

Stock-Based Compensation

The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company uses the Black-Scholes valuation model for estimating the fair value of stock options. The fair value of stock option awards is affected by the valuation assumptions, including the expected volatility based on comparable market participants, expected term of the option, risk-free interest rate and expected dividends. When a contingent cash settlement of vested options becomes probable, the Company reclassifies its vested awards to a liability and accounts for any incremental compensation cost in the period in which the settlement becomes probable.

Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).

Other (Income) Expense

Other (income) expense consisted of the following:



	Years Ended December 31,
(in thousands)	2017			2016			2015
Foreign currency (gains) losses	$	(253	)	$	853		$	1,752
Tax indemnification income	(8,367		)	(1,055		)	(1,655		)
Other income	(18		)	(18		)	(32		)
Total other (income) expense	$	(8,638	)	$	(220	)	$	65

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, comprehensive income (loss) consists of foreign currency translation gains and losses. The accumulated other comprehensive loss balance consists entirely of foreign currency translation gains and losses.

Asset Retirement Obligations

The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and probable and can be reasonably estimated. Accrual amounts are estimated based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs and a relevant discount rate, when the time periods of estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results. The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The asbestos is appropriately contained, and the Company believes it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2017 and 2016, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2017 and 2016.

Self-Insurance Reserves

The Company’s consolidated balance sheets at December 31, 2017 and 2016 include $0.5 million and $0.4 million of accrued liabilities associated with employee medical costs that are retained by the Company. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity). The Company also maintains a separate cash account to fund these medical claims and must maintain a minimum balance as determined by the plan administrator. The balance of this restricted cash account was approximately $0.1 million at both December 31, 2017 and 2016, and is included in other current assets.

Recent Accounting Standards

The following table provides a description of recent accounting pronouncements that could have a material effect on the Company’s consolidated financial statements:



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting	This ASU clarifies when to account for a change to the terms or conditions of a share–based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, vesting conditions or classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The new guidance will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for all entities. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued or made available for issuance.	January 1, 2018	The Company does not expect that the adoption of this standard will have a material impact on the Company’s consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and related additional amendments ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, ASU 2017-05, ASU 2017-10	This ASU and related amendments affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: • A full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or • A modified retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).	January 1, 2018	The Company has completed its assessment of the impact of the standards on its contract portfolio by reviewing the Company’s current accounting policies and practices and identifying differences that will result from applying the requirements of the new standard to its revenue contracts. The Company categorized its customers into multiple customer types and assessed significant customer arrangements within those customer types. The Company concluded that upon adoption of the new standard there will not be a significant impact to its revenue. The Company, in part due to the limited impact, will utilize the modified retrospective approach of adopting the ASU. The Company has identified and implemented appropriate changes to its business processes and controls to support recognition and disclosure under the new standard. Although the Company does not expect that the adoption of the new standard will have a material impact to its revenues, the Company will significantly expand its disclosures in future filings related to the qualitative and quantitative aspects of its revenue streams.
ASU 2016-02, Leases (Topic 842)	This ASU supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the statement of financial position. The provisions of ASU 2016-02 are effective for annual reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of this ASU are to be applied using a modified retrospective approach.	January 1, 2019	The Company is currently assessing the impact that this standard will have on its consolidated financial statements.



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Accounting Standards Adopted During the Year Ended December 31, 2017
ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting	ASU 2016-09 simplifies several aspects of the stock compensation guidance in Topic 718 and other related guidance providing the following amendments: • Accounting for income taxes upon vesting or exercise of share-based payments and related EPS effects • Classification of excess tax benefits on the statement of cash flows • Accounting for forfeitures • Liability classification exception for statutory tax withholding requirements • Cash flow presentation of employee taxes paid when an employer withholds shares for tax-withholding purposes • Elimination of the indefinite deferral in Topic 718	January 1, 2017	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:


•	Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•

Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).


•	Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

The Company’s financial assets measured at fair value on a recurring basis consist of money market funds. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the consolidated balance sheets at fair value using quoted prices in active markets for identical assets.

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:



	December 31, 2017
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	8,700	$	8,700	$	—	$	—
Total	$	8,700	$	8,700	$	—	$	—



	December 31, 2016
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	3,565	$	3,565	$	—	$	—
Total	$	3,565	$	3,565	$	—	$	—

Nonrecurring Fair Value Measurements

As of December 31, 2017, the Company wrote down the value of land held for sale in the U.S. segment to its fair value, less estimated costs to sell, using Level 3 inputs. See Note 7 for further discussion regarding land held for sale.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

The components of income (loss) before income taxes is summarized as follows:



	Year Ended December 31,
(in thousands)	2017		2016		2015
U.S.	$	39,559	$	23,736	$	(2,670	)
International	80		4,558		(9,108		)
Income (loss) before income taxes	$	39,639	$	28,294	$	(11,778	)

The income tax (benefit) provision is summarized as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
Current
Federal	$	(58	)	$	(91	)	$	265
State	3,242			1,689			2,386
International	16			(49		)	218
	3,200			1,549			2,869
Deferred
Federal	(71,742		)	—			—
State	(15,220		)	—			—
International	16			(17		)	99
	(86,946		)	(17		)	99
Income tax (benefit) provision	$	(83,746	)	$	1,532		$	2,968

A reconciliation of the income tax (benefit) provision with amounts determined by applying the U.S. federal income tax rate to income (loss) before income taxes is as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
U.S. statutory rate	$	13,873		$	9,903		$	(4,122	)
Permanent items	(1,916		)	(570		)	(782		)
Write-off of foreign tax and research credits	—			7,125			—
Foreign tax credits	—			(319		)	306
Uncertain tax positions	3,128			1,529			2,523
Other tax credits	(175		)	90			(120		)
State and local taxes	1,252			433			478
Impact of rate change on deferred taxes	45,129			(383		)	749
True-up of prior year tax	7			(2,751		)	1,191
Foreign tax rate differential	97			(242		)	46
Valuation allowance	(141,094		)	(13,292		)	2,704
Benefit of windfall related to stock compensation	(2,723		)	—			—
Increase in indemnification deferred tax asset	(1,055		)	—			—
Other	(269		)	9			(5		)
Income tax (benefit) provision	$	(83,746	)	$	1,532		$	2,968

The components of deferred income tax assets (liabilities) are as follows:



	December 31,
(in thousands)	2017			2016
Deferred Tax Assets
Federal benefit of state tax liabilities	$	7,510		$	11,420
Reserves, accruals and other	9,251			10,906
Inventory obsolescence	239			14,138
Capitalized research and development	9,941			18,861
Amortization of intangibles other than goodwill	3,903			8,040
Net operating loss carryforwards	63,202			80,808
Depreciation	972			492
Deferred tax assets	95,018			144,665
Deferred Tax Liabilities
Reserves, accruals and other	(1,346		)	(287		)
Customer relationships	(1,294		)	(3,398		)
Depreciation	—			—
Deferred tax liability	(2,640		)	(3,685		)
Less: valuation allowance	(5,368		)	(140,915		)
	$	87,010		$	65
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets	$	87,010		$	65

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act of 2017 (the “Act”). The Act is significant and has wide-ranging effects. The Company is still studying all of the ramifications of the Act, but expects the primary material impact will be on the Company’s ending net U.S. deferred tax assets, which have been reduced as a result of the reduction in U.S. corporate tax rates from 35% to 21% for years beginning on or after January 1, 2018. The Company recorded tax expense of $45.1 million during the year ended December 31, 2017, to reflect the impact of the Act on its ending net deferred tax assets carrying value. The Company has reviewed recent guidance issued by the U.S. Treasury concerning the repatriation transition tax. The repatriation transition tax is expected to impact U.S. entities with accumulated yet unrepatriated foreign earnings. As of December 31, 2017, the Company has no accumulated unrepatriated foreign earnings, and therefore has recorded no liability for the repatriation transition tax.

The Company regularly assesses its ability to realize its deferred tax assets, and that assessment requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed that evidence on its objective verifiability and expected impact. Historically, the Company considered its history of net operating losses, customer concentration and contractual risk, DEFINITY supplier risk, the risk of Moly supply availability and cost, and certain product development risks, which resulted in the Company recording a full valuation allowance against its domestic net deferred tax assets beginning in the year ended December 31, 2011, and each year thereafter through the year ended December 31, 2016. The Company was profitable on a cumulative basis for the three-year period ended December 31, 2017, but all of that profitability was achieved during 2017 and 2016.

During the fourth quarter of 2017, the Company determined based on its consideration of the weight of positive and negative evidence that there was sufficient positive evidence that its federal and state deferred tax assets are more-likely-than-not realizable as of December 31, 2017. The Company’s conclusion was primarily driven by the Company achieving a sustained level of profitability, the expectation of sustained future profitability, and mitigating factors related to external supplier and customer risk sufficient to outweigh the available negative evidence. Accordingly, the Company released the valuation allowance previously recorded against its domestic net deferred tax assets, resulting in an income tax benefit of $141.1 million. The Company will continue to assess the level of the valuation allowance required and if the weight of negative evidence exists in future periods to again support the recording of a partial or full valuation allowance against the Company’s U.S. deferred tax assets, that would likely have a material negative impact on the Company’s results of operations in that future period.

The Company continues to maintain a valuation allowance of $5.4 million on the portion of its foreign net deferred tax assets generated in jurisdictions with an insufficient history of cumulative profitability.

A summary of the changes in the Company’s valuation allowance is summarized below:



(in thousands)	Amount
Balance, January 1, 2015	$	152,138
Charged to income tax (benefit) provision	2,704
Foreign currency	(590		)
Deductions	—
Balance, December 31, 2015	154,252
Charged to income tax (benefit) provision	(13,292		)
Foreign currency	(45		)
Deductions	—
Balance, December 31, 2016	140,915
Charged to income tax (benefit) provision	2,305
Adoption of ASU 2016-09	2,929
Foreign currency	313
Deductions	—
Release valuation allowance	(141,094		)
Balance, December 31, 2017	$	5,368

The Company’s U.S. federal income tax returns are subject to examination for three years. The state and foreign income tax returns are subject to examination for periods varying from three to four years depending on the specific jurisdictions’ statutes of limitation.

At December 31, 2017, the Company has U.S. federal net operating loss carryovers of $233.5 million, which will begin to expire in 2030 and fully expire in 2037. The Company has Massachusetts state research credit carryforward of $2.6 million, which will expire between 2024 and 2032. The Company has Massachusetts investment tax credit carryforwards of approximately $1.1 million, of which $0.4 million have no expiration date, and the remainder of which will begin to expire in 2029 and fully expire in 2032.

The Company has concluded that an ownership change, as defined under Section 382 of the Internal Revenue Code, occurred during the year ended December 31, 2016. A Section 382 limitation now applies to the Company’s pre-change U.S. federal net operating loss carryforwards and other U.S. tax attributes. The limitation was computed based on the value of the Company just prior to the ownership change. It is the Company’s view that its ability to utilize U.S. federal net operating losses within the carryforward period is not reduced by the limitation imposed by this ownership change. However, the Company’s U.S. research credit carryforwards and U.S. foreign tax credit carryforwards will not be utilizable and as such these credits totaling $7.1 million were removed from the gross deferred tax asset balances as of December 31, 2016.

A reconciliation of the Company’s changes in uncertain tax positions for 2017, 2016 and 2015 is as follows:



(in thousands)	Amount
Balance of uncertain tax positions as of January 1, 2015	$	12,144
Additions related to current year tax positions	—
Reductions related to prior year tax positions	—
Settlements	(694		)
Lapse of statute of limitations	—
Balance of uncertain tax positions as of December 31, 2015	11,450
Additions related to current year tax positions	—
Reductions related to prior year tax positions	—
Settlements	(593		)
Lapse of statute of limitations	(416		)
Balance of uncertain tax positions as of December 31, 2016	10,441
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(506		)
Settlements	—
Lapse of statute of limitations	(69		)
Balance of uncertain tax positions as of December 31, 2017	$	9,866

As of December 31, 2017 and 2016, the total amount of unrecognized tax benefits were $9.9 million and $10.4 million, respectively, all of which, if recognized, would affect the effective tax rate. These amounts are primarily associated with domestic state tax issues, such as the allocation of income among various state tax jurisdictions.

As of December 31, 2017 and 2016, total liabilities for tax obligations and associated interest and penalties were $37.0 million and $34.4 million, respectively, consisting of income tax provisions for uncertain tax benefits of $9.9 million and $10.4 million, interest accruals of $24.9 million and $21.9 million, and penalty accruals of $2.2 million and $2.1 million, respectively. As of December 31, 2017 and 2016, $36.3 million and $33.2 million, respectively, were included in other long-term liabilities on the consolidated balance sheets and $0.7 million and $1.2 million, respectively, have reduced the Company’s deferred tax assets. Included in the 2017, 2016 and 2015 tax provisions are $3.1 million, $1.5 million and $2.5 million, respectively, relating to interest and penalties, net of benefits for reversals of uncertain tax positions and interest and penalties recognized upon settlements and lapses of relevant statutes of limitation.

In accordance with the Company’s acquisition of the medical imaging business from Bristol Myers Squibb (“BMS”) in 2008, the Company entered into a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. A long-term receivable is recorded to account for the expected value to the Company of future indemnification payments, net of actual U.S. federal tax benefits. The tax indemnification receivable is recognized within other noncurrent assets. The total noncurrent asset related to the indemnification was $26.3 million and $17.9 million at December 31, 2017 and 2016, respectively. The changes in the tax indemnification asset are recognized within other (income) expense, in the consolidated statement of operations. In accordance with the Company’s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other (income) expense. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be minimal net effect on earnings and net cash outflows related to these liabilities.

During the year ended December 31, 2017, BMS made no payments on behalf of the Company with respect to indemnified contingent tax liabilities. In 2016 and 2015, BMS, on behalf of the Company, made payments totaling $0.7 million and $1.9 million, respectively to several states in connection with prior year state income tax filings. The amount due from BMS, included within other long-term assets, increased by $8.4 million, primarily due to the decrease in U.S. corporate tax rates effective January 1, 2018. In 2016 and 2015, the amount due from BMS decreased by $1.3 million and $1.6 million for the years ended December 31, 2016, and 2015, respectively, which represented the release of asset balances associated with pre-acquisition year-related tax payments made by BMS.

Included in other (income) expense for the years ended December 31, 2017, 2016 and 2015, is tax indemnification income of $8.4 million, $1.1 million and $1.7 million, respectively. For the year ended December 31, 2017, $6.5 million of the tax indemnification income is related to the impact of the U.S. federal tax rate reduction, and the remainder arises from increases in the indemnified liabilities.

Sales of Certain International Segment Assets	12 Months Ended
Sales of Certain International Segment Assets	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Sales of Certain International Segment Assets	Sales of Certain International Segment Assets Sale of Certain Canadian Assets During the fourth quarter of 2015, the Company committed to a plan to sell certain assets and liabilities associated with the Company’s Canadian operations in the International Segment. This event qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2015. The transaction was finalized in the first quarter of 2016. Effective January 7, 2016, the Canadian subsidiary of the Company entered into an asset purchase agreement (“Canadian Asset Purchase Agreement”) pursuant to which it would sell substantially all of the assets of its Canadian radiopharmacy businesses and Gludef manufacturing and distribution business to one of its existing Canadian radiopharmacy customers. The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million, which was settled in the third quarter of 2016. The Canadian Asset Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Canadian Asset Purchase Agreement. As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with certain of the Company’s products on commercial terms and under which the buyer has agreed to certain product minimum purchase commitments. The Company does not believe the sale of certain net assets in the international segment constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company’s consolidated financial statements. This sale of assets resulted in a pre-tax book gain of $5.9 million, which is recorded within gain on sales of assets in the accompanying consolidated statements of operations for the year ended December 31, 2016. Sale of Australian Radiopharmacy Servicing Subsidiary Effective August 11, 2016, the Company entered into a share purchase agreement (“Australian Share Purchase Agreement”) with one of its existing radiopharmacy customers under which it sold all of the stock of its Australian radiopharmacy servicing subsidiary. The aggregate share sale price was AUD $2.0 million (approximately $1.5 million) in cash and also included a working capital adjustment of approximately AUD $2.0 million (approximately $1.5 million) for total proceeds of AUD $4.0 million (approximately $3.0 million) from the sale. As a result of this sale, the Company disposed of net assets of $2.2 million, primarily comprised of working capital accounts of $2.0 million. This share sale resulted in an adjusted pre-tax book gain of $0.5 million, which is recorded within gain on sales of assets in the accompanying consolidated statements of operations for the year ended December 31, 2016. As a result of the sale of the Australian subsidiary, the Company reclassified $0.4 million from other comprehensive income to gain on sale of assets in the accompanying consolidated statements of operations for the year ended December 31, 2016. The Australian Share Purchase Agreement contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Australian Share Purchase Agreement. As part of the transaction, the Company and the buyer also entered into a long-term supply and distribution contract under which the Company will supply the buyer and its subsidiaries with the Company’s products on commercial terms and under which the buyer has agreed to certain product minimum purchase commitments. The Company does not believe this sale of certain net assets in the international segment constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company’s accompanying consolidated financial statements.

Inventory

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventory

Inventory consisted of the following:



	December 31,
(in thousands)	2017		2016
Raw materials	$	10,447	$	9,658
Work in process	5,509		3,965
Finished goods	10,124		4,017
Total inventory	$	26,080	$	17,640

As of December 31, 2017 and 2016, the Company had $1.1 million and $1.2 million of inventory classified within other long‑term assets, respectively, which represent raw materials not expected to be used by the Company during the next twelve months.

Property, Plant & Equipment, Net

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant & Equipment, Net

Property, plant & equipment, net, consisted of the following:



	December 31,
(in thousands)	2017			2016
Land	$	13,450		$	14,950
Buildings	76,059			70,628
Machinery, equipment and fixtures	71,870			65,407
Computer software	20,271			18,482
Construction in progress	7,622			7,224
	189,272			176,691
Less: accumulated depreciation and amortization	(96,273		)	(82,504		)
Total property, plant & equipment, net	$	92,999		$	94,187

Depreciation and amortization expense related to property, plant & equipment, net, was $14.8 million, $12.1 million and $12.9 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Long-Lived Assets Held for Sale

During the fourth quarter of 2017, the Company committed to a plan to sell a portion of its land in the U.S. segment. This event qualified for held for sale accounting and the land was written down to its fair value, less estimated costs to sell, which is classified in other current assets in the accompanying consolidated balance sheet. This resulted in a loss of $0.9 million, which is included within general and administrative expenses in the accompanying consolidated statement of operations. The fair value was estimated utilizing Level 3 inputs and using a market approach, based on available data for transactions in the region, discussions with real estate brokers and the asking price of comparable properties in its principal market. In February 2018, the Company sold the land for net proceeds of $1.0 million.

Asset Retirement Obligations

12 Months Ended

Dec. 31, 2017

Asset Retirement Obligation Disclosure [Abstract]

Asset Retirement Obligations

The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of December 31, 2017, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.9 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.

The following table provides a summary of the changes in the Company’s asset retirement obligations:



(in thousands)	Amount
Balance, December 31, 2016	$	9,370
Accretion expense	1,042
Balance, December 31, 2017	$	10,412

Intangibles, Net

12 Months Ended

Dec. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangibles, Net

Intangibles, net, consisted of the following:



	December 31, 2017
(in thousands)	Amortization Method	Cost		Accumulated Amortization			Net
Trademarks	Straight-Line	$	13,540	$	(9,304	)	$	4,236
Customer relationships	Accelerated	99,133		(92,072		)	7,061
Patents	Straight-Line	42,780		(42,279		)	501
Total		$	155,453	$	(143,655	)	$	11,798



	December 31, 2016
(in thousands)	Amortization Method	Cost		Accumulated Amortization			Net
Trademarks	Straight-Line	$	13,540	$	(8,752	)	$	4,788
Customer relationships	Accelerated	98,926		(89,705		)	9,221
Patents	Straight-Line	42,780		(41,671		)	1,109
Total		$	155,246	$	(140,128	)	$	15,118

The Company recorded amortization expense for its intangible assets of $3.3 million, $5.1 million and $6.0 million for the years ended December 31, 2017, 2016 and 2015, respectively.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:



(in thousands)	Amount
2018	$	2,649
2019	1,806
2020	1,571
2021	1,312
2022	1,175
2023 and thereafter	3,285
Total	$	11,798

Accrued Expenses and Other Liabilities

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities

Accrued expenses are comprised of the following:



	December 31,
(in thousands)	2017		2016
Compensation and benefits	$	14,469	$	12,312
Freight, distribution and operations	3,604		2,995
Accrued rebates, discounts and chargebacks	2,860		2,297
Accrued professional fees	2,852		1,701
Other	2,751		1,944
Total accrued expenses and other liabilities	$	26,536	$	21,249

Financing Arrangements

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Financing Arrangements

On March 30, 2017, the Company refinanced its previous $365 million seven-year term loan agreement (the facility thereunder, the “2015 Term Facility”) with a new five-year $275 million term loan facility (the “2017 Term Facility” and the loans thereunder, the “Term Loans”). In addition, the Company replaced its previous $50 million five-year asset based loan facility (the “ABL Facility”) with a new $75 million five-year revolving credit facility (the “2017 Revolving Facility” and, together with the 2017 Term Facility, the “2017 Facility”). The terms of the 2017 Facility are set forth in that certain Amended and Restated Credit Agreement, dated as of March 30, 2017 (the “Credit Agreement”), by and among Holdings, the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. The 2017 Term Facility was issued net of a $0.7 million discount. The Company has the right to request an increase to the 2017 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $75.0 million, plus additional amounts, in certain circumstances.

The net proceeds of the 2017 Term Facility, together with approximately $15.3 million of cash on hand, were used to refinance in full the aggregate remaining principal amount of the loans outstanding under the 2015 Term Facility and pay related interest, transaction fees and expenses. No amounts were outstanding under the ABL Facility at that time. The Company accounted for the refinancing as both a debt extinguishment and debt modification by evaluating the refinancing on a creditor by creditor basis. The Company recorded a loss on extinguishment of debt of $2.2 million related to the write-off of unamortized debt issuance costs and incurred general and administrative expenses of $1.7 million related to third-party costs associated with the modified debt. In addition, the Company incurred and capitalized $1.6 million of new debt issuance costs related to the refinancing.

On November 29, 2017, the Company entered into Amendment No. 1 (the “Repricing Amendment”) to the 2017 Facility to, among other things, (i) reduce the applicable interest rate margins with respect to the LIBOR and Base Rate Term Loans and (ii) reduce the applicable interest rate margins with respect to the LIBOR and Base Rate Revolving Loans. The Company accounted for the Repricing Amendment as both a debt extinguishment and debt modification by evaluating the refinancing on a creditor by creditor basis. The Company recorded a loss on extinguishment of $0.2 million related to the write-off of unamortized debt issuance costs and incurred general and administrative expenses of $0.9 million related to third-party costs associated with the repricing.

2017 Term Facility

The Term Loans under the 2017 Term Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 3.75% or (ii) the Base Rate (as defined in the Credit Agreement) plus a spread of 2.75%. Interest is payable (i) with respect to LIBOR Term Loans, at the end of each Interest Period (as defined in the Credit Agreement) and (ii) with respect to Base Rate Term Loans, at the end of each quarter. At December 31, 2017, the Company’s interest rate under the 2017 Term Facility was 5.3%.

The Company is permitted to voluntarily prepay the Term Loans, in whole or in part. The 2017 Term Facility requires the Company to make mandatory prepayments of the outstanding Term Loans in certain circumstances. The 2017 Term Facility amortizes at 1.00% per year until its June 30, 2022 maturity date.

The Company’s maturities of principal obligations under the 2017 Term Facility are as follows as of December 31, 2017:



(in thousands)	Amount
2018	2,750
2019	2,750
2020	2,750
2021	2,750
2022	261,937
Total principal outstanding	272,937
Unamortized debt discount	(2,036		)
Unamortized debt issuance costs	(2,758		)
Total	268,143
Less: current portion	(2,750		)
Total long-term debt	$	265,393

2017 Revolving Facility

Under the terms of the 2017 Revolving Facility, the lenders thereunder agreed to extend credit to the Company from time to time until March 30, 2022 (the “Revolving Termination Date”) consisting of revolving loans (the “Revolving Loans” and, together with the Term Loans, the “Loans”) in an aggregate principal amount not to exceed $75.0 million (the “Revolving Commitment”) at any time outstanding. The 2017 Revolving Facility includes a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The Letters of Credit and the borrowings under the 2017 Revolving Facility are expected to be used for working capital and other general corporate purposes.

The Revolving Loans under the 2017 Revolving Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 3.00% or (ii) the Base Rate (as defined in the Credit Agreement) plus a spread of 2.00%. The 2017 Revolving Facility also includes an unused line fee, which is set at 0.38% while the Company’s secured leverage ratio (as defined in the Credit Agreement) is greater than 3.00 to 1.00 and 0.25% when the Company’s secured leverage ratio is less than or equal to 3.00 to 1.00.

The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans and Letters of Credit exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. As of December 31, 2017, there were no outstanding borrowings under the 2017 Revolving Facility.

2017 Facility Covenants

The 2017 Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The 2017 Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum consolidated leverage ratio permitted by the financial covenant is displayed in the table below:

2017 Facility Financial Covenant

Period	Consolidated Leverage Ratio
Q4 2017 through Q1 2018	5.00 to 1.00
Q2 2018 through Q1 2019	4.75 to 1.00
Thereafter	4.50 to 1.00

The 2017 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Upon an event of default, the administrative agent under the Credit Agreement will have the right to declare the Loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced.

The 2017 Facility is guaranteed by Lantheus Holdings and Lantheus MI Real Estate, LLC (“LMI-RE”), and obligations under the 2017 Facility are generally secured by first priority liens over substantially all of the assets of each of LMI, Holdings and LMI-RE (subject to customary exclusions set forth in the transaction documents) owned as of March 30, 2017 or thereafter acquired.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

Equity Incentive Plans

As of December 31, 2017, the Company’s approved equity incentive plans included the 2015 Equity Incentive Plan (“2015 Plan”), the 2013 Equity Incentive Plan (“2013 Plan”), and the 2008 Equity Incentive Plan (“2008 Plan”). These plans are administered by the Board of Directors and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights (“DERs”) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DER is treated as a separate award.

The Company has certain stock option and restricted stock awards outstanding under each of its equity incentive plans but, upon adoption of the 2015 Plan, no longer grants new equity awards under its 2008 and 2013 Plans. The Company adopted its 2015 Plan in June 2015 and subsequently amended the plan in April 2017 to increase the common stock reserved for issuance under the plan to an aggregate 5,755,277 shares.

Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:



	Year Ended December 31,
(in thousands)	2017		2016		2015
Cost of goods sold	$	1,692	$	359	$	192
Sales and marketing	640		339		254
General and administrative	2,964		1,438		1,330
Research and development	632		388		226
Total stock-based compensation expense	$	5,928	$	2,524	$	2,002

Stock Options

Stock option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.

The table below summarizes the key assumptions used in valuing stock options granted:



		Year Ended December 31, 2015
Expected volatility		26.0% - 30.0%
Expected dividends		—
Expected life (in years)		4.1 - 6.3
Risk-free interest rate		1.3% - 1.9%

There were no stock options granted during the years ended December 31, 2017 and 2016.

A summary of option activity for 2017 is presented below:



	Time Based		Performance Based		Total Stock Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at January 1, 2017	818,331		219,006		1,037,337		$	10.63
Options granted	—		—		—		$	—
Options exercised	(338,133	)	(127,099	)	(465,232	)	$	6.98
Options forfeited and expired	(2,565	)	(4,115	)	(6,680	)	$	9.47
Outstanding at December 31, 2017	477,633		87,792		565,425		$	13.65	3.9	$	4,150,751
Vested and expected to vest at December 31, 2017	477,633		87,792		565,425		$	13.65	3.9	$	4,150,751
Exercisable at December 31, 2017	371,861		87,792		459,653		$	14.94	4.4	$	2,774,300

The weighted-average grant-date fair values of options granted during the year ended December 31, 2015 was $1.44. During the years ended December 31, 2017 and 2016, 465,232 and 40,976 options were exercised having aggregate intrinsic values of $5.1 million and $0.2 million, respectively. No stock options were exercised during the year ended December 31, 2015.

As of December 31, 2017, there was no remaining unrecognized compensation expense related to outstanding stock options. In addition, performance based options contain certain contingent features, such as change in control provisions, which allow for the vesting of previously forfeited and unvested awards.

Restricted Stock

A summary of restricted stock awards activity for 2017 is presented below:



	Shares		Weighted- Average Grant Date Fair Value Per Share
Nonvested restricted stock, January 1, 2017	2,156,372		$	3.71
Granted	395,146		$	12.94
Vested	(744,244	)	$	3.86
Cancelled	(42,012	)	$	3.78
Nonvested restricted stock, December 31, 2017	1,765,262		$	5.72

As of December 31, 2017, there was $6.2 million of unrecognized compensation expense related to outstanding restricted stock, which is expected to be recognized over a weighted-average period of 1.9 years.

Performance Restricted Stock Awards

Performance awards vest based on the requisite service period subject to the achievement of specific financial performance targets. The Company monitors the probability of achieving the performance targets on a quarterly basis and may adjust periodic stock compensation expense accordingly. The performance targets include the achievement of internal performance targets only.

A summary of performance restricted stock award activity for 2017 is presented below:



	Shares		Weighted- Average Grant Date Fair Value Per Share
Nonvested performance restricted stock, January 1, 2017	—		$	—
Granted	303,495		$	16.69
Vested	—		$	—
Cancelled	(12,323	)	$	16.62
Nonvested performance restricted stock, December 31, 2017	291,172		$	16.70

As of December 31, 2017, there was $3.9 million of unrecognized compensation expense related to outstanding performance restricted stock which is expected to be recognized over a weighted-average period of 2.1 years.

Modifications

During the year ended December 31, 2017, the Company recognized approximately $1.3 million of stock-based compensation expense associated with the modification of awards held by two individuals, one of which was effectuated in the third quarter of 2017 and one of which was effectuated in the fourth quarter of 2017. The modification of these awards affected the vesting terms of the awards.

Employee Stock Purchase Plan

In April 2017, the Company’s stockholders approved the 2017 Employee Stock Purchase Plan (“2017 ESPP”), which authorized the issuance of up to 250,000 shares of common stock thereunder. Under the terms of the 2017 ESPP, eligible U.S. employees can elect to acquire shares of the Company’s common stock through periodic payroll deductions during a series of six month offering periods, which will generally begin in March and September of each year. Purchases under the 2017 ESPP are effected on the last business day of each offering period at a 15% discount to the closing price on that day. The 2017 ESPP was implemented, subject to stockholder approval, on March 10, 2017, and the first purchases thereunder were made on September 13, 2017.

Net Income (Loss) Per Common Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Income (Loss) Per Common Share

A summary of net income (loss) per common share is presented below:



	Year Ended December 31,
(in thousands, except per share amounts)	2017		2016		2015
Net income (loss)	$	123,385	$	26,762	$	(14,746	)

Basic weighted-average common shares outstanding	37,276		32,044		24,440
Effect of dilutive stock options	288		612		—
Effect of dilutive restricted stock	1,296		—		—
Effect of dilutive performance restricted stock	32		—		—
Diluted weighted-average common shares outstanding	38,892		32,656		24,440

Basic income (loss) per common share	$	3.31	$	0.84	$	(0.60	)
Diluted income (loss) per common share	$	3.17	$	0.82	$	(0.60	)

Antidilutive securities excluded from diluted net income (loss) per common share	604		1,563		2,269

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Leases and Purchase Commitments

The Company leases certain buildings, hardware and office space under operating leases and equipment under capital leases. In addition, the Company has entered into purchasing arrangements in which minimum quantities of goods or services have been committed to be purchased on an annual basis.

As of December 31, 2017, future payments required under noncancelable lease agreements and purchase commitments are as follows:



(in thousands)	Amount
2018	$	4,046
2019	2,262
2020	257
2021	235
2022	235
2023 and thereafter	412
Total	$	7,447

Rent expense was $0.3 million, $0.4 million and $0.9 million for the years ended December 31, 2017, 2016 and 2015, respectively.

The Company has entered into agreements which contain certain percentage volume purchase requirements. The Company has excluded these future purchase commitments from the table above since there are no minimum purchase commitments or payments under these agreements.

Legal Proceedings

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations.

As of December 31, 2017, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

The Company is currently in arbitration with Pharmalucence in connection with a Manufacturing and Supply Agreement dated November 12, 2013, under which Pharmalucence agreed to manufacture and supply DEFINITY for the Company. The commercial arrangement contemplated by that agreement was repeatedly delayed and ultimately never successfully realized. After extended settlement discussions between Sun Pharma, the ultimate parent of Pharmalucence, and the Company, which did not lead to a mutually acceptable outcome, on November 10, 2017, the Company filed an arbitration demand (and later an amended arbitration demand) with the American Arbitration Association (“AAA”) against Pharmalucence, alleging breach of contract, breach of the covenant of good faith and fair dealing, tortious misrepresentation and violation of the Massachusetts Consumer Protection Law, also known as Chapter 93A. The Company cannot predict the outcome of this dispute resolution proceeding and whether the Company will be able to obtain any financial recovery as a result of this proceeding.

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2017
Retirement Benefits [Abstract]
401(k) Plan	401(k) Plan The Company maintains a qualified 401(k) plan (the “401(k) Plan”) for its U.S. employees. The 401(k) Plan covers U.S. employees who meet certain eligibility requirements. Under the terms of the 401(k) Plan, the employees may elect to make tax-deferred contributions through payroll deductions within statutory and plan limits, and the Company may elect to make non-elective discretionary contributions. The Company may also make optional contributions to the 401(k) Plan for any plan year at its discretion. Expense recognized by the Company for matching contributions made to the 401(k) Plan was $1.8 million, $1.6 million and $1.6 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Related Party Transactions

12 Months Ended

Dec. 31, 2017

Related Party Transactions

Avista Capital Partners, L.P. and its affiliates (“Avista”), historically the Company’s largest stockholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company paid Avista an aggregate termination fee of $6.5 million, which is included in general and administrative expenses in the consolidated statements of operations for the year ended December 31, 2015.

In the first quarter of 2016, the Company entered into a services agreement with INC Research Holdings, Inc. (“INC”), now known as Syneos Health, Inc., to provide pharmacovigilance services. Avista and certain of its affiliates were principal owners of both INC and the Company during 2016. The agreement has a term of three years. During the year ended December 31, 2016, investment funds affiliated with Avista disposed of shares of INC common stock held by them. As a result, such investment funds were no longer a principal owner of INC. Related party expenses included in the following table represent expenses incurred during the period under which investment funds affiliated with Avista held an investment in INC.

The Company purchases inventory supplies from VWR Scientific (“VWR”). Avista and certain of its affiliates were principal owners of both VWR and the Company.

Related party expenses consisted of the following:



		Year Ended December 31,
(in thousands)	Transaction Type	2017		2016		2015
Avista Capital Partners, L.P. and its affiliates*	Offering costs paid on behalf of Avista pursuant to registration rights agreement, advisory services and other charges	$	326	$	12	$	500
Avista Capital Partners, L.P. and its affiliates*	Termination fee	—		—		6,500
INC Research Holdings, Inc.	Pharmacovigilance services	—		780		—
VWR Scientific*	Inventory supplies	297		354		300
Total related party expenses		$	623	$	1,146	$	7,300

* During the year ended December 31, 2017, Avista distributed approximately 6.3 million shares of common stock of the Company in the aggregate, representing the remainder of their holdings in the Company. The transactions were effected as distributions-in-kind of the Company’s common stock to the investors in those investment funds. As such, Avista and VWR Scientific (an entity in which Avista had an interest) are no longer related parties.

Amounts billed and unbilled for related parties included in accounts payables and accrued expenses were immaterial at December 31, 2016.

Segment Information

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Information

The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacture, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. All goodwill has been allocated to the U.S. operating segment. The Company does not identify or allocate assets to its segments.

Selected information regarding the Company’s segments are provided as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
Revenues from external customers
U.S.	$	290,002		$	257,420		$	235,824
International	41,376			44,433			57,637
Total revenues from external customers	$	331,378		$	301,853		$	293,461

Revenues by product
DEFINITY	$	157,268		$	131,612		$	111,859
TechneLite	104,644			99,217			72,562
Xenon	31,377			29,086			48,898
Other	38,089			41,938			60,142
Total revenues	$	331,378		$	301,853		$	293,461

Geographical revenues
U.S.	$	290,002		$	257,420		$	235,824
Canada	18,770			18,918			28,340
All other	22,606			25,515			29,297
Total revenues	$	331,378		$	301,853		$	293,461

Operating income
U.S.	$	49,239		$	46,909		$	42,008
International	2,614			9,679			522
Operating income	51,853			56,588			42,530
Interest expense	18,410			26,618			38,715
Debt retirement costs	—			1,896			—
Loss on extinguishment of debt	2,442			—			15,528
Other (income) expense	(8,638		)	(220		)	65
Income (loss) before income taxes	$	39,639		$	28,294		$	(11,778	)

Depreciation and amortization
U.S.	$	17,672		$	15,995		$	17,054
International	517			1,335			1,850
Total depreciation and amortization	$	18,189		$	17,330		$	18,904



	December 31,
(in thousands)	2017		2016
Long-lived assets
U.S.	$	91,537	$	92,650
International	1,462		1,537
Total long-lived assets	$	92,999	$	94,187

Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Valuation and Qualifying Accounts



(in thousands)	Balance at Beginning of Year		Charged to Income		Deductions from Reserves⁽¹⁾			Other Adjustments			Balance at End of Year
Allowance for doubtful accounts
Year ended December 31, 2017	$	969	$	136	$	(128	)	$	—		$	977
Year ended December 31, 2016	$	881	$	53	$	(30	)	$	65		$	969
Year ended December 31, 2015	$	585	$	773	$	(477	)	$	—		$	881

Rebates and allowances
Year ended December 31, 2017	$	2,297	$	9,568	$	(8,351	)	$	(654	)	$	2,860
Year ended December 31, 2016	$	2,303	$	7,255	$	(6,809	)	$	(452	)	$	2,297
Year ended December 31, 2015	$	2,164	$	6,413	$	(6,190	)	$	(84	)	$	2,303

________________________________


(1)	Amounts charged to deductions from allowance for doubtful accounts represent the write-off of uncollectible balances and represent payments for rebates and allowances.

Quarterly Consolidated Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Consolidated Financial Data (Unaudited)

Summarized quarterly consolidated financial data is presented below:



	Quarterly Periods During the Year Ended December 31, 2017
	Q1		Q2		Q3		Q4
	(in thousands, except per share data)
Revenues	$	81,359	$	88,837	$	79,941	$	81,241
Gross profit	$	39,762	$	45,947	$	38,527	$	37,899
Net income^(a)	$	4,138	$	13,595	$	8,526	$	97,126
Basic income per weighted-average share^(b)	$	0.11	$	0.37	$	0.23	$	2.58
Diluted income per weighted-average share^(b)	$	0.11	$	0.35	$	0.22	$	2.47

	Quarterly Periods During the Year Ended December 31, 2016
	Q1		Q2		Q3		Q4
	(in thousands, except per share data)
Revenues	$	76,474	$	77,966	$	73,063	$	74,350
Gross profit	$	33,701	$	35,751	$	33,681	$	34,647
Net income	$	10,323	$	7,350	$	4,220	$	4,869
Basic income per weighted-average share^(b)	$	0.34	$	0.24	$	0.14	$	0.13
Diluted income per weighted-average share^(b)	$	0.34	$	0.24	$	0.13	$	0.13

________________________________


(a)	Net income for the fourth quarter of 2017 reflects the income tax benefit due to the release of the Company’s valuation allowance of $141.1 million against its deferred tax assets offset by a provision of $45.1 million for remeasuring the Company’s deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.


(b)	Quarterly and annual computations are prepared independently. Accordingly, the sum of each quarter may not necessarily total the fiscal year period amounts noted elsewhere within this Annual Report on Form 10-K.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Reclassifications

Certain immaterial reclassifications have been made to conform the prior year consolidated financial statements and notes to the current year presentation.

Use of Estimates

Revenue Recognition

Collaboration and License Agreement with GE Healthcare Limited

Product Returns

Shipping and Handling Revenues and Costs

The Company typically does not charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in revenues.

Accounts Receivable

Rebates and Allowances

Income Taxes

Net Income (Loss) per Common Share

Cash and Cash Equivalents

Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.

Concentration of Risks and Limited Suppliers

The following table sets forth customers representing 10% or more of accounts receivable and 10% or more of revenues:



	Accounts Receivable December 31,		Revenues Year Ended December 31,
	2017	2016	2017	2016	2015
Company A	***	***	12.0%	10.3%	11.3%
Company B	14.5%	13.1%	10.4%	11.4%	11.9%
Company C	***	10.5%	10.3%	***	***

________________________________

*** Amount represented less than 10% for the reporting period.

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:



	Year Ended December 31,
	2017	2016	2015
DEFINITY	47.5%	43.6%	38.1%
TechneLite	31.6%	32.9%	24.7%
Xenon	***	***	16.7%

________________________________

*** Amount represented less than 10% of revenues for the reporting period

Inventory

Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost or market on a first-in, first-out basis.

Property, Plant & Equipment



Class		Range of Estimated Useful Lives
Buildings		10 - 50 years
Land improvements		15 - 40 years
Machinery and equipment		3 - 15 years
Furniture and fixtures		15 years
Leasehold improvements		Lesser of lease term or 15 years
Computer software		3 - 5 years

Goodwill, Intangibles and Long-Lived Assets

Goodwill

Intangible and Long-Lived Assets

Contingencies

Fair Values of Financial Instruments

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred.

Research and Development

Foreign Currency

Stock-Based Compensation

Comprehensive Income (Loss)

Asset Retirement Obligations

Self-Insurance Reserves

Recent Accounting Standards

The following table provides a description of recent accounting pronouncements that could have a material effect on the Company’s consolidated financial statements:



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting	This ASU clarifies when to account for a change to the terms or conditions of a share–based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, vesting conditions or classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The new guidance will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for all entities. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued or made available for issuance.	January 1, 2018	The Company does not expect that the adoption of this standard will have a material impact on the Company’s consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and related additional amendments ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, ASU 2017-05, ASU 2017-10	This ASU and related amendments affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: • A full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or • A modified retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).	January 1, 2018	The Company has completed its assessment of the impact of the standards on its contract portfolio by reviewing the Company’s current accounting policies and practices and identifying differences that will result from applying the requirements of the new standard to its revenue contracts. The Company categorized its customers into multiple customer types and assessed significant customer arrangements within those customer types. The Company concluded that upon adoption of the new standard there will not be a significant impact to its revenue. The Company, in part due to the limited impact, will utilize the modified retrospective approach of adopting the ASU. The Company has identified and implemented appropriate changes to its business processes and controls to support recognition and disclosure under the new standard. Although the Company does not expect that the adoption of the new standard will have a material impact to its revenues, the Company will significantly expand its disclosures in future filings related to the qualitative and quantitative aspects of its revenue streams.
ASU 2016-02, Leases (Topic 842)	This ASU supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the statement of financial position. The provisions of ASU 2016-02 are effective for annual reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of this ASU are to be applied using a modified retrospective approach.	January 1, 2019	The Company is currently assessing the impact that this standard will have on its consolidated financial statements.



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Accounting Standards Adopted During the Year Ended December 31, 2017
ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting	ASU 2016-09 simplifies several aspects of the stock compensation guidance in Topic 718 and other related guidance providing the following amendments: • Accounting for income taxes upon vesting or exercise of share-based payments and related EPS effects • Classification of excess tax benefits on the statement of cash flows • Accounting for forfeitures • Liability classification exception for statutory tax withholding requirements • Cash flow presentation of employee taxes paid when an employer withholds shares for tax-withholding purposes • Elimination of the indefinite deferral in Topic 718	January 1, 2017	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Customer Concentration Risk

The following table sets forth customers representing 10% or more of accounts receivable and 10% or more of revenues:



	Accounts Receivable December 31,		Revenues Year Ended December 31,
	2017	2016	2017	2016	2015
Company A	***	***	12.0%	10.3%	11.3%
Company B	14.5%	13.1%	10.4%	11.4%	11.9%
Company C	***	10.5%	10.3%	***	***

________________________________

*** Amount represented less than 10% for the reporting period

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:



	Year Ended December 31,
	2017	2016	2015
DEFINITY	47.5%	43.6%	38.1%
TechneLite	31.6%	32.9%	24.7%
Xenon	***	***	16.7%

________________________________

*** Amount represented less than 10% of revenues for the reporting period

Schedule of Product Concentration Risk

The following table sets forth customers representing 10% or more of accounts receivable and 10% or more of revenues:



	Accounts Receivable December 31,		Revenues Year Ended December 31,
	2017	2016	2017	2016	2015
Company A	***	***	12.0%	10.3%	11.3%
Company B	14.5%	13.1%	10.4%	11.4%	11.9%
Company C	***	10.5%	10.3%	***	***

________________________________

*** Amount represented less than 10% for the reporting period

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:



	Year Ended December 31,
	2017	2016	2015
DEFINITY	47.5%	43.6%	38.1%
TechneLite	31.6%	32.9%	24.7%
Xenon	***	***	16.7%

________________________________

*** Amount represented less than 10% of revenues for the reporting period

Estimated Useful Lives of Major Classes of Depreciable Assets

The estimated useful lives of the major classes of depreciable assets are as follows:



Class		Range of Estimated Useful Lives
Buildings		10 - 50 years
Land improvements		15 - 40 years
Machinery and equipment		3 - 15 years
Furniture and fixtures		15 years
Leasehold improvements		Lesser of lease term or 15 years
Computer software		3 - 5 years

Schedule of Other Income (Expense), Net

Other (income) expense consisted of the following:



	Years Ended December 31,
(in thousands)	2017			2016			2015
Foreign currency (gains) losses	$	(253	)	$	853		$	1,752
Tax indemnification income	(8,367		)	(1,055		)	(1,655		)
Other income	(18		)	(18		)	(32		)
Total other (income) expense	$	(8,638	)	$	(220	)	$	65

Recent Accounting Pronouncements

The following table provides a description of recent accounting pronouncements that could have a material effect on the Company’s consolidated financial statements:



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting	This ASU clarifies when to account for a change to the terms or conditions of a share–based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, vesting conditions or classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The new guidance will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for all entities. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued or made available for issuance.	January 1, 2018	The Company does not expect that the adoption of this standard will have a material impact on the Company’s consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and related additional amendments ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, ASU 2017-05, ASU 2017-10	This ASU and related amendments affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: • A full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or • A modified retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).	January 1, 2018	The Company has completed its assessment of the impact of the standards on its contract portfolio by reviewing the Company’s current accounting policies and practices and identifying differences that will result from applying the requirements of the new standard to its revenue contracts. The Company categorized its customers into multiple customer types and assessed significant customer arrangements within those customer types. The Company concluded that upon adoption of the new standard there will not be a significant impact to its revenue. The Company, in part due to the limited impact, will utilize the modified retrospective approach of adopting the ASU. The Company has identified and implemented appropriate changes to its business processes and controls to support recognition and disclosure under the new standard. Although the Company does not expect that the adoption of the new standard will have a material impact to its revenues, the Company will significantly expand its disclosures in future filings related to the qualitative and quantitative aspects of its revenue streams.
ASU 2016-02, Leases (Topic 842)	This ASU supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the statement of financial position. The provisions of ASU 2016-02 are effective for annual reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of this ASU are to be applied using a modified retrospective approach.	January 1, 2019	The Company is currently assessing the impact that this standard will have on its consolidated financial statements.



Standard	Description	Effective Date for Company	Effect on the Consolidated Financial Statements
Accounting Standards Adopted During the Year Ended December 31, 2017
ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting	ASU 2016-09 simplifies several aspects of the stock compensation guidance in Topic 718 and other related guidance providing the following amendments: • Accounting for income taxes upon vesting or exercise of share-based payments and related EPS effects • Classification of excess tax benefits on the statement of cash flows • Accounting for forfeitures • Liability classification exception for statutory tax withholding requirements • Cash flow presentation of employee taxes paid when an employer withholds shares for tax-withholding purposes • Elimination of the indefinite deferral in Topic 718	January 1, 2017	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:



	December 31, 2017
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	8,700	$	8,700	$	—	$	—
Total	$	8,700	$	8,700	$	—	$	—



	December 31, 2016
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	3,565	$	3,565	$	—	$	—
Total	$	3,565	$	3,565	$	—	$	—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Components of Income (Loss) Before Income Taxes

The components of income (loss) before income taxes is summarized as follows:



	Year Ended December 31,
(in thousands)	2017		2016		2015
U.S.	$	39,559	$	23,736	$	(2,670	)
International	80		4,558		(9,108		)
Income (loss) before income taxes	$	39,639	$	28,294	$	(11,778	)

Schedule of Tax (Benefit) Provision

The income tax (benefit) provision is summarized as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
Current
Federal	$	(58	)	$	(91	)	$	265
State	3,242			1,689			2,386
International	16			(49		)	218
	3,200			1,549			2,869
Deferred
Federal	(71,742		)	—			—
State	(15,220		)	—			—
International	16			(17		)	99
	(86,946		)	(17		)	99
Income tax (benefit) provision	$	(83,746	)	$	1,532		$	2,968

Differences in Provision for Income Taxes from Amount Computed by Applying Statutory U.S. Federal Income Tax Rate to Income (Loss) from Operations Before Income Taxes

A reconciliation of the income tax (benefit) provision with amounts determined by applying the U.S. federal income tax rate to income (loss) before income taxes is as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
U.S. statutory rate	$	13,873		$	9,903		$	(4,122	)
Permanent items	(1,916		)	(570		)	(782		)
Write-off of foreign tax and research credits	—			7,125			—
Foreign tax credits	—			(319		)	306
Uncertain tax positions	3,128			1,529			2,523
Other tax credits	(175		)	90			(120		)
State and local taxes	1,252			433			478
Impact of rate change on deferred taxes	45,129			(383		)	749
True-up of prior year tax	7			(2,751		)	1,191
Foreign tax rate differential	97			(242		)	46
Valuation allowance	(141,094		)	(13,292		)	2,704
Benefit of windfall related to stock compensation	(2,723		)	—			—
Increase in indemnification deferred tax asset	(1,055		)	—			—
Other	(269		)	9			(5		)
Income tax (benefit) provision	$	(83,746	)	$	1,532		$	2,968

Components of Deferred Income Tax Assets (Liabilities)

The components of deferred income tax assets (liabilities) are as follows:



	December 31,
(in thousands)	2017			2016
Deferred Tax Assets
Federal benefit of state tax liabilities	$	7,510		$	11,420
Reserves, accruals and other	9,251			10,906
Inventory obsolescence	239			14,138
Capitalized research and development	9,941			18,861
Amortization of intangibles other than goodwill	3,903			8,040
Net operating loss carryforwards	63,202			80,808
Depreciation	972			492
Deferred tax assets	95,018			144,665
Deferred Tax Liabilities
Reserves, accruals and other	(1,346		)	(287		)
Customer relationships	(1,294		)	(3,398		)
Depreciation	—			—
Deferred tax liability	(2,640		)	(3,685		)
Less: valuation allowance	(5,368		)	(140,915		)
	$	87,010		$	65
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets	$	87,010		$	65

Reconciliation of Uncertain Tax Positions

A reconciliation of the Company’s changes in uncertain tax positions for 2017, 2016 and 2015 is as follows:



(in thousands)	Amount
Balance of uncertain tax positions as of January 1, 2015	$	12,144
Additions related to current year tax positions	—
Reductions related to prior year tax positions	—
Settlements	(694		)
Lapse of statute of limitations	—
Balance of uncertain tax positions as of December 31, 2015	11,450
Additions related to current year tax positions	—
Reductions related to prior year tax positions	—
Settlements	(593		)
Lapse of statute of limitations	(416		)
Balance of uncertain tax positions as of December 31, 2016	10,441
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(506		)
Settlements	—
Lapse of statute of limitations	(69		)
Balance of uncertain tax positions as of December 31, 2017	$	9,866

Reconciliation of Valuation Allowance

A summary of the changes in the Company’s valuation allowance is summarized below:



(in thousands)	Amount
Balance, January 1, 2015	$	152,138
Charged to income tax (benefit) provision	2,704
Foreign currency	(590		)
Deductions	—
Balance, December 31, 2015	154,252
Charged to income tax (benefit) provision	(13,292		)
Foreign currency	(45		)
Deductions	—
Balance, December 31, 2016	140,915
Charged to income tax (benefit) provision	2,305
Adoption of ASU 2016-09	2,929
Foreign currency	313
Deductions	—
Release valuation allowance	(141,094		)
Balance, December 31, 2017	$	5,368

Inventory (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consisted of the following:



	December 31,
(in thousands)	2017		2016
Raw materials	$	10,447	$	9,658
Work in process	5,509		3,965
Finished goods	10,124		4,017
Total inventory	$	26,080	$	17,640

Property, Plant & Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant & Equipment, Net

Property, plant & equipment, net, consisted of the following:



	December 31,
(in thousands)	2017			2016
Land	$	13,450		$	14,950
Buildings	76,059			70,628
Machinery, equipment and fixtures	71,870			65,407
Computer software	20,271			18,482
Construction in progress	7,622			7,224
	189,272			176,691
Less: accumulated depreciation and amortization	(96,273		)	(82,504		)
Total property, plant & equipment, net	$	92,999		$	94,187

Asset Retirement Obligations (Tables)

12 Months Ended

Dec. 31, 2017

Asset Retirement Obligation Disclosure [Abstract]

Summary of Asset Retirement Obligations

The following table provides a summary of the changes in the Company’s asset retirement obligations:



(in thousands)	Amount
Balance, December 31, 2016	$	9,370
Accretion expense	1,042
Balance, December 31, 2017	$	10,412

Intangibles, Net (Tables)

12 Months Ended

Dec. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of Intangibles, Net

Intangibles, net, consisted of the following:



	December 31, 2017
(in thousands)	Amortization Method	Cost		Accumulated Amortization			Net
Trademarks	Straight-Line	$	13,540	$	(9,304	)	$	4,236
Customer relationships	Accelerated	99,133		(92,072		)	7,061
Patents	Straight-Line	42,780		(42,279		)	501
Total		$	155,453	$	(143,655	)	$	11,798



	December 31, 2016
(in thousands)	Amortization Method	Cost		Accumulated Amortization			Net
Trademarks	Straight-Line	$	13,540	$	(8,752	)	$	4,788
Customer relationships	Accelerated	98,926		(89,705		)	9,221
Patents	Straight-Line	42,780		(41,671		)	1,109
Total		$	155,246	$	(140,128	)	$	15,118

Schedule of Expected Future Amortization Expense

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:



(in thousands)	Amount
2018	$	2,649
2019	1,806
2020	1,571
2021	1,312
2022	1,175
2023 and thereafter	3,285
Total	$	11,798

Accrued Expenses and Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses are comprised of the following:



	December 31,
(in thousands)	2017		2016
Compensation and benefits	$	14,469	$	12,312
Freight, distribution and operations	3,604		2,995
Accrued rebates, discounts and chargebacks	2,860		2,297
Accrued professional fees	2,852		1,701
Other	2,751		1,944
Total accrued expenses and other liabilities	$	26,536	$	21,249

Financing Arrangements (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility

The Company’s maturities of principal obligations under the 2017 Term Facility are as follows as of December 31, 2017:



(in thousands)	Amount
2018	2,750
2019	2,750
2020	2,750
2021	2,750
2022	261,937
Total principal outstanding	272,937
Unamortized debt discount	(2,036		)
Unamortized debt issuance costs	(2,758		)
Total	268,143
Less: current portion	(2,750		)
Total long-term debt	$	265,393

Schedule of Term Facility Financial Covenants

The maximum consolidated leverage ratio permitted by the financial covenant is displayed in the table below:

2017 Facility Financial Covenant

Period	Consolidated Leverage Ratio
Q4 2017 through Q1 2018	5.00 to 1.00
Q2 2018 through Q1 2019	4.75 to 1.00
Thereafter	4.50 to 1.00

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Expense Recognized

Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:



	Year Ended December 31,
(in thousands)	2017		2016		2015
Cost of goods sold	$	1,692	$	359	$	192
Sales and marketing	640		339		254
General and administrative	2,964		1,438		1,330
Research and development	632		388		226
Total stock-based compensation expense	$	5,928	$	2,524	$	2,002

Schedule of Assumptions used in Valuing Stock Options Granted

The table below summarizes the key assumptions used in valuing stock options granted:



		Year Ended December 31, 2015
Expected volatility		26.0% - 30.0%
Expected dividends		—
Expected life (in years)		4.1 - 6.3
Risk-free interest rate		1.3% - 1.9%

Summary of Option Activity

A summary of option activity for 2017 is presented below:



	Time Based		Performance Based		Total Stock Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at January 1, 2017	818,331		219,006		1,037,337		$	10.63
Options granted	—		—		—		$	—
Options exercised	(338,133	)	(127,099	)	(465,232	)	$	6.98
Options forfeited and expired	(2,565	)	(4,115	)	(6,680	)	$	9.47
Outstanding at December 31, 2017	477,633		87,792		565,425		$	13.65	3.9	$	4,150,751
Vested and expected to vest at December 31, 2017	477,633		87,792		565,425		$	13.65	3.9	$	4,150,751
Exercisable at December 31, 2017	371,861		87,792		459,653		$	14.94	4.4	$	2,774,300

Summary of Restricted Stock Awards Activity

A summary of performance restricted stock award activity for 2017 is presented below:



	Shares		Weighted- Average Grant Date Fair Value Per Share
Nonvested performance restricted stock, January 1, 2017	—		$	—
Granted	303,495		$	16.69
Vested	—		$	—
Cancelled	(12,323	)	$	16.62
Nonvested performance restricted stock, December 31, 2017	291,172		$	16.70

A summary of restricted stock awards activity for 2017 is presented below:



	Shares		Weighted- Average Grant Date Fair Value Per Share
Nonvested restricted stock, January 1, 2017	2,156,372		$	3.71
Granted	395,146		$	12.94
Vested	(744,244	)	$	3.86
Cancelled	(42,012	)	$	3.78
Nonvested restricted stock, December 31, 2017	1,765,262		$	5.72

Net Income (Loss) Per Common Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Summary of Net Income (Loss) Per Common Share

A summary of net income (loss) per common share is presented below:



	Year Ended December 31,
(in thousands, except per share amounts)	2017		2016		2015
Net income (loss)	$	123,385	$	26,762	$	(14,746	)

Basic weighted-average common shares outstanding	37,276		32,044		24,440
Effect of dilutive stock options	288		612		—
Effect of dilutive restricted stock	1,296		—		—
Effect of dilutive performance restricted stock	32		—		—
Diluted weighted-average common shares outstanding	38,892		32,656		24,440

Basic income (loss) per common share	$	3.31	$	0.84	$	(0.60	)
Diluted income (loss) per common share	$	3.17	$	0.82	$	(0.60	)

Antidilutive securities excluded from diluted net income (loss) per common share	604		1,563		2,269

Commitments (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of of Future Payments Required Under Noncancelable Lease Agreements and Purchase Commitments

As of December 31, 2017, future payments required under noncancelable lease agreements and purchase commitments are as follows:



(in thousands)	Amount
2018	$	4,046
2019	2,262
2020	257
2021	235
2022	235
2023 and thereafter	412
Total	$	7,447

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2017

Summary of Related Party Expenses

Related party expenses consisted of the following:



		Year Ended December 31,
(in thousands)	Transaction Type	2017		2016		2015
Avista Capital Partners, L.P. and its affiliates*	Offering costs paid on behalf of Avista pursuant to registration rights agreement, advisory services and other charges	$	326	$	12	$	500
Avista Capital Partners, L.P. and its affiliates*	Termination fee	—		—		6,500
INC Research Holdings, Inc.	Pharmacovigilance services	—		780		—
VWR Scientific*	Inventory supplies	297		354		300
Total related party expenses		$	623	$	1,146	$	7,300

Segment Information (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Schedule of Selected Information for Each Business Segment

Selected information regarding the Company’s segments are provided as follows:



	Year Ended December 31,
(in thousands)	2017			2016			2015
Revenues from external customers
U.S.	$	290,002		$	257,420		$	235,824
International	41,376			44,433			57,637
Total revenues from external customers	$	331,378		$	301,853		$	293,461

Revenues by product
DEFINITY	$	157,268		$	131,612		$	111,859
TechneLite	104,644			99,217			72,562
Xenon	31,377			29,086			48,898
Other	38,089			41,938			60,142
Total revenues	$	331,378		$	301,853		$	293,461

Geographical revenues
U.S.	$	290,002		$	257,420		$	235,824
Canada	18,770			18,918			28,340
All other	22,606			25,515			29,297
Total revenues	$	331,378		$	301,853		$	293,461

Operating income
U.S.	$	49,239		$	46,909		$	42,008
International	2,614			9,679			522
Operating income	51,853			56,588			42,530
Interest expense	18,410			26,618			38,715
Debt retirement costs	—			1,896			—
Loss on extinguishment of debt	2,442			—			15,528
Other (income) expense	(8,638		)	(220		)	65
Income (loss) before income taxes	$	39,639		$	28,294		$	(11,778	)

Depreciation and amortization
U.S.	$	17,672		$	15,995		$	17,054
International	517			1,335			1,850
Total depreciation and amortization	$	18,189		$	17,330		$	18,904



	December 31,
(in thousands)	2017		2016
Long-lived assets
U.S.	$	91,537	$	92,650
International	1,462		1,537
Total long-lived assets	$	92,999	$	94,187

Valuation and Qualifying Accounts (Tables)

12 Months Ended

Dec. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts



(in thousands)	Balance at Beginning of Year		Charged to Income		Deductions from Reserves⁽¹⁾			Other Adjustments			Balance at End of Year
Allowance for doubtful accounts
Year ended December 31, 2017	$	969	$	136	$	(128	)	$	—		$	977
Year ended December 31, 2016	$	881	$	53	$	(30	)	$	65		$	969
Year ended December 31, 2015	$	585	$	773	$	(477	)	$	—		$	881

Rebates and allowances
Year ended December 31, 2017	$	2,297	$	9,568	$	(8,351	)	$	(654	)	$	2,860
Year ended December 31, 2016	$	2,303	$	7,255	$	(6,809	)	$	(452	)	$	2,297
Year ended December 31, 2015	$	2,164	$	6,413	$	(6,190	)	$	(84	)	$	2,303

________________________________


(1)	Amounts charged to deductions from allowance for doubtful accounts represent the write-off of uncollectible balances and represent payments for rebates and allowances.

Quarterly Consolidated Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Financial Information

Summarized quarterly consolidated financial data is presented below:



	Quarterly Periods During the Year Ended December 31, 2017
	Q1		Q2		Q3		Q4
	(in thousands, except per share data)
Revenues	$	81,359	$	88,837	$	79,941	$	81,241
Gross profit	$	39,762	$	45,947	$	38,527	$	37,899
Net income^(a)	$	4,138	$	13,595	$	8,526	$	97,126
Basic income per weighted-average share^(b)	$	0.11	$	0.37	$	0.23	$	2.58
Diluted income per weighted-average share^(b)	$	0.11	$	0.35	$	0.22	$	2.47

	Quarterly Periods During the Year Ended December 31, 2016
	Q1		Q2		Q3		Q4
	(in thousands, except per share data)
Revenues	$	76,474	$	77,966	$	73,063	$	74,350
Gross profit	$	33,701	$	35,751	$	33,681	$	34,647
Net income	$	10,323	$	7,350	$	4,220	$	4,869
Basic income per weighted-average share^(b)	$	0.34	$	0.24	$	0.14	$	0.13
Diluted income per weighted-average share^(b)	$	0.34	$	0.24	$	0.13	$	0.13

________________________________


(a)	Net income for the fourth quarter of 2017 reflects the income tax benefit due to the release of the Company’s valuation allowance of $141.1 million against its deferred tax assets offset by a provision of $45.1 million for remeasuring the Company’s deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.


(b)	Quarterly and annual computations are prepared independently. Accordingly, the sum of each quarter may not necessarily total the fiscal year period amounts noted elsewhere within this Annual Report on Form 10-K.

Description of Business - Additional Information (Detail)	Dec. 31, 2017 commercial_product
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of commercial products	9

Summary of Significant Accounting Policies - Collaboration and License Agreement with GE Healthcare Limited (Details) - Collaborative Arrangement, Product - GE Healthcare - USD ($)		12 Months Ended
	Apr. 25, 2017	Dec. 31, 2017
Schedule Of Accounting Policies [Line Items]
Upfront payment under license agreement	$ 5,000,000	$ 5,000,000
Revenue recognition expectation based on milestone	$ 60,000,000
Revenue recognized based on milestone		$ 0

Summary of Significant Accounting Policies - Shipping and Handling Revenue and Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Shipping and handling costs	$ 14.3	$ 13.6	$ 17.4

Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Miscellaneous receivables	$ 0.8	$ 0.7

Summary of Significant Accounting Policies - Schedule of Customer and Product Concentration Risk (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounts Receivable \| Customer Concentration Risk \| Company B
Concentration Risk [Line Items]
Concentration risk percentage	14.50%	13.10%
Accounts Receivable \| Customer Concentration Risk \| Company C
Concentration Risk [Line Items]
Concentration risk percentage		10.50%
Revenues \| Customer Concentration Risk \| Company A
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	10.30%	11.30%
Revenues \| Customer Concentration Risk \| Company B
Concentration Risk [Line Items]
Concentration risk percentage	10.40%	11.40%	11.90%
Revenues \| Customer Concentration Risk \| Company C
Concentration Risk [Line Items]
Concentration risk percentage	10.30%
Net Product Revenue \| Product Concentration Risk \| DEFINITY
Concentration Risk [Line Items]
Concentration risk percentage	47.50%	43.60%	38.10%
Net Product Revenue \| Product Concentration Risk \| TechneLite
Concentration Risk [Line Items]
Concentration risk percentage	31.60%	32.90%	24.70%
Net Product Revenue \| Product Concentration Risk \| Xenon
Concentration Risk [Line Items]
Concentration risk percentage			16.70%

Summary of Significant Accounting Policies - Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Inventory without regulatory approval	$ 0	$ 0

Summary of Significant Accounting Policies - Estimated Useful Lives of Major Classes of Depreciable Assets (Detail)	12 Months Ended
	Dec. 31, 2017
Computer software \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	3 years
Computer software \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	5 years
Buildings
Property, Plant & Equipment [Line Items]
Estimated useful lives	10 years
Buildings \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	50 years
Land improvements \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Land improvements \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	40 years
Machinery and equipment \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	3 years
Machinery and equipment \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Furniture and fixtures \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Leasehold improvements \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years

Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Advertising and promotion costs	$ 4.4	$ 3.6	$ 3.1

Summary of Significant Accounting Policies - Other (Income) Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Foreign currency (gains) losses	$ (253)	$ 853	$ 1,752
Tax indemnification income	(8,367)	(1,055)	(1,655)
Other income	(18)	(18)	(32)
Total other (income) expense	$ (8,638)	$ (220)	$ 65

Summary of Accounting Policies - Self-Insurance Reserves (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Accrued liabilities associated with employee medical costs	$ 0.5	$ 0.4
Restricted cash account	$ 0.1	$ 0.1

Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 8,700	$ 3,565
Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	8,700	3,565
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	8,700	3,565
Level 1 \| Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	8,700	3,565
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Level 2 \| Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
Level 3 \| Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 0	$ 0

Income taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S.	$ 39,559	$ 23,736	$ (2,670)
International	80	4,558	(9,108)
Income (loss) before income taxes	$ 39,639	$ 28,294	$ (11,778)

Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current
Federal	$ (58)	$ (91)	$ 265
State	3,242	1,689	2,386
International	16	(49)	218
Current provision (benefit) for income taxes	3,200	1,549	2,869
Deferred
Federal	(71,742)	0	0
State	(15,220)	0	0
International	16	(17)	99
Deferred provision (benefit) for income taxes	(86,946)	(17)	99
Income tax (benefit) provision	$ (83,746)	$ 1,532	$ 2,968

Income Taxes - Differences in Provision for Income Taxes from Amount Computed by Applying Statutory U.S. Federal Income Tax Rate to Income (Loss) from Operations Before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. statutory rate		$ 13,873	$ 9,903	$ (4,122)
Permanent items		(1,916)	(570)	(782)
Write-off of foreign tax and research credits		0	7,125	0
Foreign tax credits		0	(319)	306
Uncertain tax positions		3,128	1,529	2,523
Other tax credits		(175)	90	(120)
State and local taxes		1,252	433	478
Impact of rate change on deferred taxes	$ 45,100	45,129	(383)	749
True-up of prior year tax		7	(2,751)	1,191
Foreign tax rate differential		97	(242)	46
Valuation allowance	$ (141,100)	(141,094)
Valuation allowance			(13,292)	2,704
Benefit of windfall related to stock compensation		(2,723)	0	0
Increase in indemnification deferred tax asset		(1,055)	0	0
Other		(269)	9	(5)
Income tax (benefit) provision		$ (83,746)	$ 1,532	$ 2,968

Income Taxes - Components of Deferred Income Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets
Federal benefit of state tax liabilities	$ 7,510	$ 11,420
Reserves, accruals and other	9,251	10,906
Inventory obsolescence	239	14,138
Capitalized research and development	9,941	18,861
Amortization of intangibles other than goodwill	3,903	8,040
Net operating loss carryforwards	63,202	80,808
Depreciation	972	492
Deferred tax assets	95,018	144,665
Deferred Tax Liabilities
Reserves, accruals and other	(1,346)	(287)
Customer relationships	(1,294)	(3,398)
Depreciation	0	0
Deferred tax liability	(2,640)	(3,685)
Less: valuation allowance	(5,368)	(140,915)	$ (154,252)	$ (152,138)
Net deferred tax liabilities	87,010	65
Recorded in the accompanying consolidated balance sheets as
Reserves, accruals and other	$ 87,010	$ 65

Income Taxes - Reconciliation of Uncertain Tax Positions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance of uncertain tax positions	$ 10,441		$ 11,450
Additions related to current year tax positions	0	$ 0	0
Reductions related to prior year tax positions	(506)	0	0
Settlements	0	(593)	(694)
Lapse of statute of limitations	(69)	(416)	$ 0
Ending balance of uncertain tax positions	$ 9,866	$ 10,441

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes And Tax Related [Line Items]
Impact of rate change on deferred taxes	$ 45,100,000	$ 45,129,000	$ (383,000)	$ 749,000
Tax on unrepatriated foreign earnings	0	0
Valuation allowance	(141,100,000)	(141,094,000)
Deferred tax asset, valuation allowance	5,368,000	$ 5,368,000	140,915,000	154,252,000	$ 152,138,000
Examination period of income tax returns		3 years
Write-off of foreign tax and research credits		$ 0	7,125,000	0
Unrecognized tax benefits	9,866,000	9,866,000	10,441,000		$ 11,450,000	$ 12,144,000
Reductions related to prior year tax positions		(506,000)	0	0
Total liabilities for tax obligation and associated interest and penalties	37,000,000	37,000,000	34,400,000
Income tax provisions for uncertain tax benefits	9,900,000	9,900,000	10,400,000
Interest accruals	24,900,000	24,900,000	21,900,000
Penalty accruals	2,200,000	2,200,000	2,100,000
Other tax long-term liabilities	36,300,000	36,300,000	33,200,000
Uncertain tax positions		3,128,000	1,529,000	2,523,000
Total noncurrent assets related to indemnification	26,300,000	26,300,000	17,900,000
Tax indemnification income		8,367,000	1,055,000	1,655,000
Federal
Income Taxes And Tax Related [Line Items]
Net operating loss carryovers	233,500,000	233,500,000
Tax indemnification income		6,500,000
State Research Credit
Income Taxes And Tax Related [Line Items]
Tax credits	2,600,000	2,600,000
Massachusetts \| Investment Tax Credits
Income Taxes And Tax Related [Line Items]
Tax credits	1,100,000	1,100,000
Net operating loss carryovers without expiration date	400,000	$ 400,000
Minimum \| State and Local Jurisdiction
Income Taxes And Tax Related [Line Items]
Examination period of income tax returns		3 years
Minimum \| Federal
Income Taxes And Tax Related [Line Items]
Operating loss carryovers, year of expiration		2030
Minimum \| State Research Credit
Income Taxes And Tax Related [Line Items]
Tax credit carryforward, year of expiration		2024
Maximum \| State and Local Jurisdiction
Income Taxes And Tax Related [Line Items]
Examination period of income tax returns		4 years
Maximum \| Federal
Income Taxes And Tax Related [Line Items]
Operating loss carryovers, year of expiration		2037
Maximum \| State Research Credit
Income Taxes And Tax Related [Line Items]
Tax credit carryforward, year of expiration		2032
BMS
Income Taxes And Tax Related [Line Items]
Payments for state income tax settlements		$ 0	700,000	1,900,000
Decrease in amount due from BMS included within other long-term assets		8,400,000	1,300,000	$ 1,600,000
Deferred Tax Assets
Income Taxes And Tax Related [Line Items]
Penalty accruals	$ 700,000	$ 700,000	$ 1,200,000

Income Taxes - Reconciliation of Valuation Allowance (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance [Line Items]
Balance at the beginning of the period		$ 140,915	$ 154,252	$ 152,138
Charged to provision for income taxes		2,305	(13,292)	2,704
Foreign currency		(313)	45	590
Deductions		0	0	0
Release valuation allowance	$ 141,100	141,094
Balance at the end of the period	$ 5,368	$ 5,368	140,915	$ 154,252
Accounting Standards Update 2016-09
Valuation Allowance [Line Items]
Adoption of ASU 2016-09			$ 2,929

Sales of Certain International Segment Assets - Additional Information (Detail) $ in Thousands, $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2016 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 AUD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Gain on sale of assets		$ 0		$ 6,385	$ 0
Canadian Radiopharmacies and Gludef Manufacturing and Distribution Business
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Purchase price for asset sale	$ 9,000
Working capital adjustment	$ 500
Gain on sale of assets				5,900
Australian Radiopharmacy Servicing Subsidiary
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Gain on sale of assets				500
Share sale price			$ 2.0	1,500
Working capital adjustment in sale of stock units			2.0	1,500
Gross proceeds from sale of stock units			$ 4.0	3,000
Net proceeds from sale of stock units				2,200
Working Capital Assets Liabilities Sold				2,000
Reclassification from other comprehensive income to gain on sales of assets				$ (400)

Inventory - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 10,447	$ 9,658
Work in process	5,509	3,965
Finished goods	10,124	4,017
Total inventory	$ 26,080	$ 17,640

Inventory - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Other Noncurrent Assets
Inventory [Line Items]
Raw materials	$ 1.1	$ 1.2

Property, Plant & and Equipment, Net - Schedule of Property, Plant & Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	$ 189,272	$ 176,691
Less: accumulated depreciation and amortization	(96,273)	(82,504)
Total property, plant & equipment, net	92,999	94,187
Land
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	13,450	14,950
Buildings
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	76,059	70,628
Machinery, equipment and fixtures
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	71,870	65,407
Construction in progress
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	7,622	7,224
Computer software
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	$ 20,271	$ 18,482

Property, Plant & Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 28, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant & Equipment [Line Items]
Depreciation and amortization		$ 18,189	$ 17,330	$ 18,904
Loss on impairment of land		912	0	0
Property, Plant and Equipment
Property, Plant & Equipment [Line Items]
Depreciation and amortization		$ 14,800	$ 12,100	$ 12,900
Subsequent Event
Property, Plant & Equipment [Line Items]
Proceeds from sale of excess land	$ 1,000

Asset Retirement Obligations - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Financial assurance in form of surety bond	$ 28.2
Asset retirement obligation liabilities expected, present value	$ 26.9

Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Balance at the beginning of the period	$ 9,370
Accretion expense	1,042
Balance at the ending of the period	$ 10,412

Intangibles, Net - Schedule of Intangibles, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 155,453	$ 155,246
Accumulated Amortization	(143,655)	(140,128)
Net	11,798	15,118
Trademarks
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated Amortization	(9,304)	(8,752)
Net	4,236	4,788
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	99,133	98,926
Accumulated Amortization	(92,072)	(89,705)
Net	7,061	9,221
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	42,780	42,780
Accumulated Amortization	(42,279)	(41,671)
Net	$ 501	$ 1,109

Intangibles, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Amortization expense	$ 3.3	$ 5.1	$ 6.0

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2018	$ 2,649
2019	1,806
2020	1,571
2021	1,312
2022	1,175
2023 and thereafter	3,285
Net	$ 11,798	$ 15,118

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Compensation and benefits	$ 14,469	$ 12,312
Freight, distribution and operations	3,604	2,995
Accrued rebates, discounts and chargebacks	2,860	2,297
Accrued professional fees	2,852	1,701
Other	2,751	1,944
Total accrued expenses and other liabilities	$ 26,536	$ 21,249

Financing Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 30, 2017	Dec. 29, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt and debt retirement costs	$ (2,200,000)	$ 200,000	$ (2,442,000)	$ (1,896,000)	$ (15,528,000)
Third-party costs associated with modified debt	1,700,000
Debt issuance costs	1,600,000
Cost associated with debt repricing		$ 900,000
2015 Term Facility
Debt Instrument [Line Items]
Debt instrument, face amount	$ 365,000,000
Debt instrument, term (in years)	7 years
Cash paid during the execution of refinancing	$ 15,300,000
Aggregate principal amount outstanding	0
Revolving Line of Credit
Debt Instrument [Line Items]
Debt instrument, face amount	$ 75,000,000		75,000,000
Debt instrument, term (in years)	5 years
2017 Term Facility
Debt Instrument [Line Items]
Debt instrument, face amount	$ 275,000,000
Debt instrument, term (in years)	5 years
Debt instrument, discount amount	$ 700,000
Increase in aggregate principal amount	75,000,000
Aggregate principal amount outstanding			$ 272,937,000
Asset Based Loan (ABL) Facility
Debt Instrument [Line Items]
Debt instrument, face amount	$ 50,000,000
Debt instrument, term (in years)	5 years

Financing Arrangements - Term Facility (Details) - 2017 Term Facility	12 Months Ended
	Dec. 31, 2017
Debt Instrument [Line Items]
Interest rate at end of period	5.30%
Amortization (in percent)	1.00%
LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	3.75%
Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	2.75%

Financing Arrangements - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Less: current portion	$ (2,750)	$ (3,650)
Total long-term debt	265,393	$ 274,460
2017 Term Facility
Debt Instrument [Line Items]
2018	2,750
2019	2,750
2020	2,750
2021	2,750
2022	261,937
Total principal outstanding	272,937
Unamortized debt discount	(2,036)
Unamortized debt issuance costs	(2,758)
Total	268,143
Less: current portion	(2,750)
Total long-term debt	$ 265,393

Financing Arrangements - Revolving Facility (Details) - Revolving Credit Facility - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 30, 2017
Debt Instrument [Line Items]
Debt instrument, face amount	$ 75,000,000	$ 75,000,000
Outstanding borrowing	$ 0
Leverage Ratio Range One
Debt Instrument [Line Items]
Unused line of credit fee (in percentage)	0.38%
Debt instrument covenant leverage ratio	300.00%
Leverage Ratio Range Two
Debt Instrument [Line Items]
Unused line of credit fee (in percentage)	0.25%
Debt instrument covenant leverage ratio	300.00%
LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	3.00%
Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	2.00%
Letter of Credit
Debt Instrument [Line Items]
Debt instrument, face amount	$ 20,000,000

Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail) - 2017 Facility	12 Months Ended
	Dec. 31, 2017
Q4 2017 through Q1 2018
Debt Instrument [Line Items]
Debt instrument covenant leverage ratio	500.00%
Q2 2018 through Q1 2019
Debt Instrument [Line Items]
Debt instrument covenant leverage ratio	475.00%
Thereafter
Debt Instrument [Line Items]
Debt instrument covenant leverage ratio	450.00%

Stock-Based Compensation - Equity Incentive Plans (Details)	Dec. 31, 2017 shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share based compensation, shares authorized (in shares)	5,755,277

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,928	$ 2,524	$ 2,002
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,692	359	192
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	640	339	254
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,964	1,438	1,330
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 632	$ 388	$ 226

Stock-Based Compensation - Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term	10 years
Options granted (in shares)	0	0
Weighted average grant-date fair value of options granted (in dollars per share)		$ 1.44
Options exercised (in shares)	465,232	40,976	0
Total unrecognized compensation costs	$ 0
Liability awards	$ 1,300,000
Time Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Options granted (in shares)	0
Options exercised (in shares)	338,133
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of option exercised (in shares)	$ 5,100,000	$ 200,000

Stock-Based Compensation - Schedule of Assumptions used in Valuing Stock Options Granted (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0	0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum		1.30%
Risk-free interest rate, maximum		1.90%
Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		26.00%
Expected life (in years)		4 years 1 month 6 days
Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		30.00%
Expected life (in years)		6 years 3 months 18 days

Stock-Based Compensation - Schedule of Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total Stock Options
Options outstanding, beginning balance (in shares)	1,037,337
Options granted (in shares)	0	0
Options exercised (in shares)	(465,232)	(40,976)	0
Options forfeited and expired (in shares)	(6,680)
Options outstanding, ending balance (in shares)	565,425	1,037,337
Vested and expected to vest (in shares)	565,425
Exercisable (in shares)	459,653
Weighted- Average Exercise Price
Options outstanding, beginning balance, weighted average exercise price (in dollars per share)	$ 10.63
Options granted, weighted average exercise price (in dollars per share)	0.00
Options exercised, weighted average exercise price (in dollars per share)	6.98
Options forfeited and expired, weighted average exercise price (in dollars per share)	9.47
Options outstanding, ending balance, weighted average exercise price (in dollars per share)	13.65	$ 10.63
Vested and expected to vest, weighted average exercise price (in dollars per share)	13.65
Exercisable, weighted average exercise price (in dollars per share)	$ 14.94
Stock Option Activity, Additional Disclosures
Options outstanding, weighted average remaining contractual term (in years)	3 years 10 months 24 days
Vested and expected to vest, weighted average remaining contractual term (in years)	3 years 10 months 24 days
Exercisable, weighted average remaining contractual term (in years)	4 years 4 months 24 days
Options outstanding, aggregate intrinsic value	$ 4,150,751
Vested and expected to vest, aggregate intrinsic value	4,150,751
Exercisable, aggregate intrinsic value	$ 2,774,300
Time Based
Total Stock Options
Options outstanding, beginning balance (in shares)	818,331
Options granted (in shares)	0
Options exercised (in shares)	(338,133)
Options forfeited and expired (in shares)	(2,565)
Options outstanding, ending balance (in shares)	477,633	818,331
Vested and expected to vest (in shares)	477,633
Exercisable (in shares)	371,861
Performance Based
Total Stock Options
Options outstanding, beginning balance (in shares)	219,006
Options granted (in shares)	0
Options exercised (in shares)	(127,099)
Options forfeited and expired (in shares)	(4,115)
Options outstanding, ending balance (in shares)	87,792	219,006
Vested and expected to vest (in shares)	87,792
Exercisable (in shares)	87,792

Stock-Based Compensation - Summary of Restricted Stock Awards Activity (Detail) - Restricted Stock $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Shares
Non-vested restricted stock, beginning balance (in shares) \| shares	2,156,372
Granted (in shares) \| shares	395,146
Vested (in shares) \| shares	(744,244)
Cancelled (in shares) \| shares	(42,012)
Non-vested restricted stock, ending balance (in shares) \| shares	1,765,262
Weighted- Average Grant Date Fair Value Per Share
Weighted average grant date fair value per share, non-vested restricted stock, beginning balance (in dollars per share) \| $ / shares	$ 3.71
Weighted average grant date fair value per share, granted (in dollars per share) \| $ / shares	12.94
Weighted average grant date fair value per share, vested (in dollars per share) \| $ / shares	3.86
Weighted average grant date fair value per share, forfeited (in dollars per share) \| $ / shares	3.78
Weighted average grant date fair value per share, non-vested restricted stock, ending balance (in dollars per share) \| $ / shares	$ 5.72
Unrecognized compensation expense \| $	$ 6.2
Weighted-average remaining period for recognition of unrecognized compensation costs (in years)	1 year 10 months 24 days

Stock-Based Compensation - Summary of Performance Restricted Stock Awards Activity (Details) - Performance Restricted Stock $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Shares
Non-vested restricted stock, beginning balance (in shares) \| shares	0
Granted (in shares) \| shares	303,495
Vested (in shares) \| shares	0
Cancelled (in shares) \| shares	(12,323)
Non-vested restricted stock, ending balance (in shares) \| shares	291,172
Weighted- Average Grant Date Fair Value Per Share
Weighted average grant date fair value per share, non-vested restricted stock, beginning balance (in dollars per share) \| $ / shares	$ 0.00
Weighted average grant date fair value per share, granted (target) (in dollars per share) \| $ / shares	16.69
Weighted average grant date fair value per share, vested (in dollars per share) \| $ / shares	0.00
Weighted average grant date fair value per share, forfeited (in dollars per share) \| $ / shares	16.62
Weighted average grant date fair value per share, non-vested restricted stock, ending balance (in dollars per share) \| $ / shares	$ 16.70
Unrecognized compensation expense \| $	$ 3.9
Weighted-average remaining period for recognition of unrecognized compensation costs (in years)	2 years 1 month 6 days

Stock-Based Compensation - Modifications (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense	$ 1.3

Stock-based Compensation - Employee Stock Purchase Plan (Details) - shares	Apr. 27, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shares authorized (in shares)		5,755,277
2017 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shares authorized (in shares)	250,000
Employee stock purchase plan discount percentage	15.00%

Net Income (Loss) Per Common Share - Summary of Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Line Items]
Net income (loss)									$ 123,385	$ 26,762	$ (14,746)
Basic weighted-average common shares outstanding (in shares)									37,276	32,044	24,440
Effect of dilutive stock options (in shares)									288	612	0
Effect of dilutive restricted stock (in shares)									1,296	0	0
Effect of dilutive performance restricted stock (in shares)									32	0	0
Diluted weighted-average common shares outstanding (in shares)									38,892	32,656	24,440
Basic income (loss) per common share outstanding (in dollars per share)	$ 2.58	$ 0.23	$ 0.37	$ 0.11	$ 0.13	$ 0.14	$ 0.24	$ 0.34	$ 3.31	$ 0.84	$ (0.60)
Diluted income (loss) per common share outstanding (in dollars per share)	$ 2.47	$ 0.22	$ 0.35	$ 0.11	$ 0.13	$ 0.13	$ 0.24	$ 0.34	$ 3.17	$ 0.82	$ (0.60)
Stock Options \| Nonvested Restricted Stock
Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted income (loss) per common share (in shares)									604	1,563	2,269

Commitments - Schedule of Minimum Lease and Purchase Commitments Under Noncancelable Arrangements (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 4,046
2019	2,262
2020	257
2021	235
2022	235
2023 and thereafter	412
Total	$ 7,447

Commitments - Additional Information (Detail) - USD ($)	12 Months Ended
Commitments - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 300,000	$ 400,000	$ 900,000
Minimum purchase commitments or payments under agreements	$ 0

401(k) Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Expenses recognized for matching contributions	$ 1.8	$ 1.6

Related Party Transactions - Summary of Related Party Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Total related party expenses	$ 623	$ 1,146	$ 7,300
Pharmacovigilance \| INC
Related Party Transaction [Line Items]
Total related party expenses	0	780	0
Avista \| Advisory Services and Other Charges
Related Party Transaction [Line Items]
Total related party expenses	326	12	500
Avista \| Termination Fee
Related Party Transaction [Line Items]
Total related party expenses	0	0	6,500
VWR \| Inventory Supplies
Related Party Transaction [Line Items]
Total related party expenses	$ 297	$ 354	$ 300

Related Party Transactions - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2015
Related Party Transaction [Line Items]
Distributions-in-kind of common stock (in shares)	6.3
Advisory Services and Monitoring Agreement
Related Party Transaction [Line Items]
Annual fee	$ 1.0
Term of agreement	7 years
Aggregate termination fee paid		$ 6.5
INC Research Holdings, Inc.
Related Party Transaction [Line Items]
Term of agreement	3 years

Segment Information - Additional Information (Detail)	12 Months Ended
Segment Information - Additional Information (Detail)	Dec. 31, 2017 segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment Information - Schedule of Selected Information for Each Business Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenues	$ 331,378	$ 301,853	$ 293,461
Operating income
Operating income	51,853	56,588	42,530
Interest expense	18,410	26,618	38,715
Debt retirement costs	0	1,896	0
Loss on extinguishment of debt	(2,442)	0	(15,528)
Other (income) expense	8,638	220	(65)
Income (loss) before income taxes	39,639	28,294	(11,778)
Depreciation and amortization	18,189	17,330	18,904
Long-lived assets	92,999	94,187
DEFINITY
Segment Reporting Information [Line Items]
Revenues	157,268	131,612	111,859
TechneLite
Segment Reporting Information [Line Items]
Revenues	104,644	99,217	72,562
Xenon
Segment Reporting Information [Line Items]
Revenues	31,377	29,086	48,898
Other
Segment Reporting Information [Line Items]
Revenues	38,089	41,938	60,142
U.S.
Segment Reporting Information [Line Items]
Revenues	290,002	257,420	235,824
Canada
Segment Reporting Information [Line Items]
Revenues	18,770	18,918	28,340
All other
Segment Reporting Information [Line Items]
Revenues	22,606	25,515	29,297
U.S.
Segment Reporting Information [Line Items]
Revenues	290,002	257,420	235,824
Operating income
Operating income	49,239	46,909	42,008
Depreciation and amortization	17,672	15,995	17,054
Long-lived assets	91,537	92,650
International
Segment Reporting Information [Line Items]
Revenues	41,376	44,433	57,637
Operating income
Operating income	2,614	9,679	522
Depreciation and amortization	517	1,335	$ 1,850
Long-lived assets	$ 1,462	$ 1,537

Valuation and Qualifying Accounts - Schedule of Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Deductions from Reserves	$ 0	$ 0	$ 0
Allowance for doubtful accounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	969	881	585
Charged to Income	136	53	773
Deductions from Reserves	(128)	(30)	(477)
Other Adjustments	0	65	0
Balance at End of Year	977	969	881
Rebates and allowances
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	2,297	2,303	2,164
Charged to Income	9,568	7,255	6,413
Deductions from Reserves	(8,351)	(6,809)	(6,190)
Other Adjustments	(654)	(452)	(84)
Balance at End of Year	$ 2,860	$ 2,297	$ 2,303

Quarterly Consolidated Financial Data - Summary of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 81,241	$ 79,941	$ 88,837	$ 81,359	$ 74,350	$ 73,063	$ 77,966	$ 76,474
Gross profit	37,899	38,527	45,947	39,762	34,647	33,681	35,751	33,701	$ 162,135	$ 137,780	$ 135,522
Net income	$ 97,126	$ 8,526	$ 13,595	$ 4,138	$ 4,869	$ 4,220	$ 7,350	$ 10,323
Basic income per weighted-average share (in dollars per share)	$ 2.58	$ 0.23	$ 0.37	$ 0.11	$ 0.13	$ 0.14	$ 0.24	$ 0.34	$ 3.31	$ 0.84	$ (0.60)
Diluted income per weighted-average share (in dollars per share)	$ 2.47	$ 0.22	$ 0.35	$ 0.11	$ 0.13	$ 0.13	$ 0.24	$ 0.34	$ 3.17	$ 0.82	$ (0.60)
Valuation allowance	$ (141,100)								$ (141,094)
Impact of rate change on deferred taxes	$ 45,100								$ 45,129	$ (383)	$ 749